Pamela Kunz, MD

• Alyssa Ann Grimshaw
• Cary Gross
• Daniel Boffa
• Darrick K. Li
• Dhanpat Jain
• Donna Spiegelman
• Henry S. Park
• Jeremy Kortmansky
• Jill Lacy
• Kevin Billingsley
• Kimberly L. Johung
• Melinda Irwin
• Michael Cecchini
• Nadine Housri
• Nita Ahuja
• Rong Wang
• Sajid A Khan
• Stacey Stein
• Wajih Kidwai
• Xavier Llor
• Xiaomei Ma

Neuroendocrine Tumors

• Where Are All the Women in Industry Advisory Boards?Shroff R, Goodman K, Mehnert J, Vose J, Moran S, Yessaian J, Baldo L, Alexander B, Highsmith Q, Mills J, Kunz P. Where Are All the Women in Industry Advisory Boards? Journal Of Clinical Oncology 2022, jco2102219. PMID: 36331246, DOI: 10.1200/jco.21.02219.
• Exploratory genomic analysis of high-grade neuroendocrine neoplasms across diverse primary sites.Sun TY, Zhao L, Van Hummelen P, Martin B, Hornbacker K, Lee H, Xia LC, Padda SK, Ji HP, Kunz P. Exploratory genomic analysis of high-grade neuroendocrine neoplasms across diverse primary sites. Endocrine Related Cancer 2022, 29: 665-679. PMID: 36165930, DOI: 10.1530/erc-22-0015.
• A phase II study of sapanisertib (TAK-228) a mTORC1/2 inhibitor in rapalog-resistant advanced pancreatic neuroendocrine tumors (PNET): ECOG-ACRIN EA2161Rajdev L, Lee JW, Libutti SK, Benson AB, Fisher GA, Kunz PL, Hendifar AE, Catalano P, O’Dwyer P. A phase II study of sapanisertib (TAK-228) a mTORC1/2 inhibitor in rapalog-resistant advanced pancreatic neuroendocrine tumors (PNET): ECOG-ACRIN EA2161 Investigational New Drugs 2022, 40: 1306-1314. PMID: 36264382, PMCID: PMC9795724, DOI: 10.1007/s10637-022-01311-w.
• A Randomized Study of Temozolomide or Temozolomide and Capecitabine in Patients with Advanced Pancreatic Neuroendocrine Tumors (ECOG-ACRIN E2211).Kunz PL, Graham NT, Catalano PJ, Nimeiri HS, Fisher GA, Longacre TA, Suarez CJ, Martin BA, Yao JC, Kulke MH, Hendifar AE, Shanks JC, Shah MH, Zalupski MM, Schmulbach EL, Reidy-Lagunes DL, Strosberg JR, O'Dwyer PJ, Benson AB. A Randomized Study of Temozolomide or Temozolomide and Capecitabine in Patients with Advanced Pancreatic Neuroendocrine Tumors (ECOG-ACRIN E2211). Journal Of Clinical Oncology 2022, 101200jco2201013. PMID: 36260828, DOI: 10.1200/jco.22.01013.
• Correction: Phase II Study Evaluating 2 Dosing Schedules of Oral Foretinib (GSK1363089), cMET/VEGFR2 Inhibitor, in Patients with Metastatic Gastric CancerShah MA, Wainberg ZA, Catenacci DVT, Hochster HS, Ford J, Kunz P, Lee FC, Kallender H, Cecchi F, Rabe DC, Keer H, Martin AM, Liu Y, Gagnon R, Bonate P, Liu L, Gilmer T, Bottaro DP. Correction: Phase II Study Evaluating 2 Dosing Schedules of Oral Foretinib (GSK1363089), cMET/VEGFR2 Inhibitor, in Patients with Metastatic Gastric Cancer PLOS ONE 2022, 17: e0276211. PMID: 36215283, PMCID: PMC9550092, DOI: 10.1371/journal.pone.0276211.
• Gender analysis of oncology expert participation on online professional platforms.Kunzman J, Henry E, Housri N, Kamran S, Kunz P, Lee L, LoConte N, Burt L. Gender analysis of oncology expert participation on online professional platforms. Journal Of Clinical Oncology 2022, 40: 350-350. DOI: 10.1200/jco.2022.40.28_suppl.350.
• Understanding Modern Medical Centers: Beyond Simone-Intersectional Maxims for a New Era.Graff SL, Wildes T, Duma N, Dizon DS, LoConte NK, Mitchell E, Murphy MC, Perez EA, Temkin SM, Kunz PL, Winkfield KM. Understanding Modern Medical Centers: Beyond Simone-Intersectional Maxims for a New Era. Journal Of Clinical Oncology 2022, jco2201060. PMID: 36166718, DOI: 10.1200/jco.22.01060.
• 92: [177Lu]Lu-Dota-Tate as First-Line Therapy for Patients with Grade 2 and 3 Advanced Gastroenteropancreatic Neuroendocrine Tumours (GEP-NETS): The NETTER-2 StudyMyrehaug S, Singh S, Pavel M, Kunz P, de Herder W, Herrmann K, D’Amelio A, Santoro P, Folitar I, Ferone D. 92: [177Lu]Lu-Dota-Tate as First-Line Therapy for Patients with Grade 2 and 3 Advanced Gastroenteropancreatic Neuroendocrine Tumours (GEP-NETS): The NETTER-2 Study Radiotherapy And Oncology 2022, 174: s40-s41. DOI: 10.1016/s0167-8140(22)04371-7.
• Examination of speakership gender disparity at an international oncology conference.Caro J, Boatwright C, Li X, Fiocco C, Stempel J, Stoeckle J, Smithy J, Betof Warner A, Shum E, Sabari J, Malhotra J, Chan N, Spencer K, Kunz P, Goldberg J, Mehnert J. Examination of speakership gender disparity at an international oncology conference. Journal Of Clinical Oncology 2022, 40: 11002-11002. DOI: 10.1200/jco.2022.40.16_suppl.11002.
• A randomized study of temozolomide or temozolomide and capecitabine in patients with advanced pancreatic neuroendocrine tumors: Final analysis of efficacy and evaluation of MGMT (ECOG-ACRIN E2211).Kunz P, Graham N, Catalano P, Nimeiri H, Fisher G, Longacre T, Suarez C, Rubin D, Yao J, Kulke M, Hendifar A, Shanks J, Shah M, Zalupski M, Schmulbach E, Reidy D, Strosberg J, Wong T, O'Dwyer P, Benson A. A randomized study of temozolomide or temozolomide and capecitabine in patients with advanced pancreatic neuroendocrine tumors: Final analysis of efficacy and evaluation of MGMT (ECOG-ACRIN E2211). Journal Of Clinical Oncology 2022, 40: 4004-4004. DOI: 10.1200/jco.2022.40.16_suppl.4004.
• Microangiopathic Hemolytic Anemia Is a Late and Fatal Complication of Gastric Signet Ring Cell Carcinoma: A Systematic Review and Case-Control StudyLam R, Tarangelo N, Wang R, Horibe M, Grimshaw AA, Jain D, Haffar S, Bazerbachi F, Kunz PL, Li DK. Microangiopathic Hemolytic Anemia Is a Late and Fatal Complication of Gastric Signet Ring Cell Carcinoma: A Systematic Review and Case-Control Study The Oncologist 2022, 27: 751-759. PMID: 35589098, PMCID: PMC9438916, DOI: 10.1093/oncolo/oyac093.
• Everolimus with or without bevacizumab in advanced pNET: CALGB 80701 (Alliance).Kulke MH, Ou FS, Niedzwiecki D, Huebner L, Kunz P, Kennecke HF, Wolin EM, Chan JA, O'Reilly EM, Meyerhardt JA, Venook A. Everolimus with or without bevacizumab in advanced pNET: CALGB 80701 (Alliance). Endocrine Related Cancer 2022, 29: 335-344. PMID: 35324465, PMCID: PMC9257687, DOI: 10.1530/erc-21-0239.
• Analyse finale de la survie globale dans l’étude de phase 3 NETTER-1 du Lu-DOTATATE chez les patients atteints de tumeurs neuroendocrines de l’intestin moyenRuszniewski P, Strosberg J, Caplin M, Kunz P, Bodei L, Hendifar A, Mittra E, Wolin E, Yao J, Pavel M, Grande E, van Cutsem E, Seregni E, Duarte H, Niepel D, Demange A, Krenning E. Analyse finale de la survie globale dans l’étude de phase 3 NETTER-1 du Lu-DOTATATE chez les patients atteints de tumeurs neuroendocrines de l’intestin moyen Nuklearmedizin - NuclearMedicine 2022, 46: 49-50. DOI: 10.1016/j.mednuc.2022.01.004.
• Correction: Phase II Study Evaluating 2 Dosing Schedules of Oral Foretinib (GSK1363089), cMET/VEGFR2 Inhibitor, in Patients with Metastatic Gastric CancerShah MA, Wainberg ZA, Catenacci DVT, Hochster HS, Ford J, Kunz P, Lee FC, Kallender H, Cecchi F, Rabe DC, Keer H, Martin AM, Liu Y, Gagnon R, Bonate P, Liu L, Gilmer T, Bottaro DP. Correction: Phase II Study Evaluating 2 Dosing Schedules of Oral Foretinib (GSK1363089), cMET/VEGFR2 Inhibitor, in Patients with Metastatic Gastric Cancer PLOS ONE 2021, 16: e0261994. PMID: 34941969, PMCID: PMC8699912, DOI: 10.1371/journal.pone.0261994.
• Diffuse idiopathic pulmonary neuroendocrine cell hyperplasia: clinical characteristics and progression to carcinoid tumourSun TY, Hwang G, Pancirer D, Hornbacker K, Codima A, Lui NS, Raj R, Kunz P, Padda SK. Diffuse idiopathic pulmonary neuroendocrine cell hyperplasia: clinical characteristics and progression to carcinoid tumour European Respiratory Journal 2021, 59: 2101058. PMID: 34795035, PMCID: PMC8792466, DOI: 10.1183/13993003.01058-2021.
• 177Lu-Dotatate plus long-acting octreotide versus high‑dose long-acting octreotide in patients with midgut neuroendocrine tumours (NETTER-1): final overall survival and long-term safety results from an open-label, randomised, controlled, phase 3 trialStrosberg JR, Caplin ME, Kunz PL, Ruszniewski PB, Bodei L, Hendifar A, Mittra E, Wolin EM, Yao JC, Pavel ME, Grande E, Van Cutsem E, Seregni E, Duarte H, Gericke G, Bartalotta A, Mariani MF, Demange A, Mutevelic S, Krenning EP, investigators N. 177Lu-Dotatate plus long-acting octreotide versus high‑dose long-acting octreotide in patients with midgut neuroendocrine tumours (NETTER-1): final overall survival and long-term safety results from an open-label, randomised, controlled, phase 3 trial The Lancet Oncology 2021, 22: 1752-1763. PMID: 34793718, DOI: 10.1016/s1470-2045(21)00572-6.
• Pre-Operative Chemoradiotherapy With or Without Induction Chemotherapy for Operable Locally-Advanced Esophageal Cancer.Peters GW, Wang S, Peters NV, Dhanasopan A, Lacy J, Cecchini M, Kortmansky JS, Stein S, Kunz PL, Lattanzi S, Park HSM, Boffa D, Johung KL, Jethwa KR. Pre-Operative Chemoradiotherapy With or Without Induction Chemotherapy for Operable Locally-Advanced Esophageal Cancer. International Journal Of Radiation Oncology, Biology, Physics 2021, 111: e68. PMID: 34701946, DOI: 10.1016/j.ijrobp.2021.07.422.
• Pre-Operative Chemoradiotherapy With or Without Induction Chemotherapy for Operable Locally-Advanced Esophageal CancerPeters G, Wang S, Peters N, Dhanasopan A, Lacy J, Cecchini M, Kortmansky J, Stein S, Kunz P, Lattanzi S, Park H, Boffa D, Johung K, Jethwa K. Pre-Operative Chemoradiotherapy With or Without Induction Chemotherapy for Operable Locally-Advanced Esophageal Cancer International Journal Of Radiation Oncology • Biology • Physics 2021, 111: e68. DOI: 10.1016/j.ijrobp.2021.07.422.
• Making Sense of a Complex Disease: A Practical Approach to Managing Neuroendocrine TumorsZhang JY, Kunz PL. Making Sense of a Complex Disease: A Practical Approach to Managing Neuroendocrine Tumors JCO Oncology Practice 2021, 18: 258-264. PMID: 34652954, DOI: 10.1200/op.21.00240.
• Comparison of Design, Eligibility, and Outcomes of Neuroendocrine Neoplasm Trials Initiated From 2000 to 2009 vs 2010 to 2020Das S, Du L, Lee CL, Arhin ND, Chan JA, Kohn EC, Halperin DM, Berlin J, LaFerriere H, Singh S, Kunz PL, Dasari A. Comparison of Design, Eligibility, and Outcomes of Neuroendocrine Neoplasm Trials Initiated From 2000 to 2009 vs 2010 to 2020 JAMA Network Open 2021, 4: e2131744. PMID: 34705010, PMCID: PMC8552059, DOI: 10.1001/jamanetworkopen.2021.31744.
• 1102P The phase III NETTER-1 study of 177Lu-DOTATATE in patients with midgut neuroendocrine tumours: Further survival analysesRuszniewski P, Caplin M, Kunz P, Bodei L, Hendifar A, Mittra E, Wolin E, Yao J, Pavel M, Grande E, Van Cutsem E, Seregni E, Duarte H, Demange A, Mutevelic S, Krenning E, Strosberg J. 1102P The phase III NETTER-1 study of 177Lu-DOTATATE in patients with midgut neuroendocrine tumours: Further survival analyses Annals Of Oncology 2021, 32: s911-s912. DOI: 10.1016/j.annonc.2021.08.184.
• Temozolomide in Grade 3 Gastroenteropancreatic Neuroendocrine Neoplasms: A Multicenter Retrospective ReviewChan DL, Bergsland EK, Chan JA, Gadgil R, Halfdanarson TR, Hornbacker K, Kelly V, Kunz PL, McGarrah PW, Raj NP, Reidy DL, Thawer A, Whitman J, Wu L, Becker C, Singh S. Temozolomide in Grade 3 Gastroenteropancreatic Neuroendocrine Neoplasms: A Multicenter Retrospective Review The Oncologist 2021, 26: 950-955. PMID: 34342086, PMCID: PMC8571741, DOI: 10.1002/onco.13923.
• Rapid Progression After 177Lu-DOTATATE in Patients With Neuroendocrine Tumors.Assi HA, Hornbacker K, Shaheen S, Wittenberg T, Silberman R, Kunz PL. Rapid Progression After 177Lu-DOTATATE in Patients With Neuroendocrine Tumors. Pancreas 2021, 50: 890-894. PMID: 34398071, DOI: 10.1097/mpa.0000000000001841.
• Abstract 898: Survival for patients with early-onset colorectal cancer - An overall survival analysis from the National Cancer Database, 2004-2015Cheng E, Cheng E, Blackburn H, Ng K, Ng K, Spiegelman D, Irwin M, Ma X, Gross C, Tabung F, Tabung F, Giovannucci E, Giovannucci E, Kunz P, Llor X, Billingsley K, Meyerhardt J, Meyerhardt J, Ahuja N, Fuchs C. Abstract 898: Survival for patients with early-onset colorectal cancer - An overall survival analysis from the National Cancer Database, 2004-2015 Cancer Research 2021, 81: 898-898. DOI: 10.1158/1538-7445.am2021-898.
• O-2 Overall survival and long-term safety data from the NETTER-1 trial: 177-Lu-Dotatate vs. high-dose octreotide in patients with progressive midgut NETsStrosberg J, Caplin M, Kunz P, Ruszniewski P, Bodei L, Hendifar A, Mittra E, Wolin E, Yao J, Pavel M, Pulido E, Van Cutsem E, Seregni E, Duarte H, Gericke G, Bartalotta A, Demange A, Mutevelic S, Krenning E. O-2 Overall survival and long-term safety data from the NETTER-1 trial: 177-Lu-Dotatate vs. high-dose octreotide in patients with progressive midgut NETs Annals Of Oncology 2021, 32: s217-s218. DOI: 10.1016/j.annonc.2021.05.006.
• Analysis of Survival Among Adults With Early-Onset Colorectal Cancer in the National Cancer DatabaseCheng E, Blackburn HN, Ng K, Spiegelman D, Irwin ML, Ma X, Gross CP, Tabung FK, Giovannucci EL, Kunz PL, Llor X, Billingsley K, Meyerhardt JA, Ahuja N, Fuchs CS. Analysis of Survival Among Adults With Early-Onset Colorectal Cancer in the National Cancer Database JAMA Network Open 2021, 4: e2112539. PMID: 34132794, PMCID: PMC8209612, DOI: 10.1001/jamanetworkopen.2021.12539.
• Final overall survival in the phase 3 NETTER-1 study of lutetium-177-DOTATATE in patients with midgut neuroendocrine tumors.Strosberg J, Caplin M, Kunz P, Ruszniewski P, Bodei L, Hendifar A, Mittra E, Wolin E, Yao J, Pavel M, Grande E, Van Cutsem E, Seregni E, Duarte H, Gericke G, Bartalotta A, Demange A, Mutevelic S, Krenning E, group O. Final overall survival in the phase 3 NETTER-1 study of lutetium-177-DOTATATE in patients with midgut neuroendocrine tumors. Journal Of Clinical Oncology 2021, 39: 4112-4112. DOI: 10.1200/jco.2021.39.15_suppl.4112.
• The North American Neuroendocrine Tumor Society Consensus Guidelines for Surveillance and Management of Metastatic and/or Unresectable Pheochromocytoma and Paraganglioma.Fishbein L, Del Rivero J, Else T, Howe JR, Asa SL, Cohen DL, Dahia PLM, Fraker DL, Goodman KA, Hope TA, Kunz PL, Perez K, Perrier ND, Pryma DA, Ryder M, Sasson AR, Soulen MC, Jimenez C. The North American Neuroendocrine Tumor Society Consensus Guidelines for Surveillance and Management of Metastatic and/or Unresectable Pheochromocytoma and Paraganglioma. Pancreas 2021, 50: 469-493. PMID: 33939658, DOI: 10.1097/mpa.0000000000001792.
• Pituitary Neoplasm Nomenclature Workshop: Does Adenoma Stand the Test of Time?Ho K, Fleseriu M, Kaiser U, Salvatori R, Brue T, Lopes MB, Kunz P, Molitch M, Camper SA, Gadelha M, Syro LV, Laws E, Reincke M, Nishioka H, Grossman A, Barkan A, Casanueva F, Wass J, Mamelak A, Katznelson L, van der Lely AJ, Radovick S, Bidlingmaier M, Boguszewski M, Bollerslev J, Hoffman AR, Oyesiku N, Raverot G, Ben-Shlomo A, Fowkes R, Shimon I, Fukuoka H, Pereira AM, Greenman Y, Heaney AP, Gurnell M, Johannsson G, Osamura RY, Buchfelder M, Zatelli MC, Korbonits M, Chanson P, Biermasz N, Clemmons DR, Karavitaki N, Bronstein MD, Trainer P, Melmed S. Pituitary Neoplasm Nomenclature Workshop: Does Adenoma Stand the Test of Time? Journal Of The Endocrine Society 2021, 5: bvaa205. PMID: 33604494, PMCID: PMC7874572, DOI: 10.1210/jendso/bvaa205.
• MA12.09 Retrospective Analysis of DIPNECH and Carcinoid Tumorlets as Precursors to Invasive Pulmonary Carcinoid TumorsSun T, Codima A, Hwang G, Hornbacker K, Pancirer D, Lui N, Raj R, Kunz P, Padda S. MA12.09 Retrospective Analysis of DIPNECH and Carcinoid Tumorlets as Precursors to Invasive Pulmonary Carcinoid Tumors Journal Of Thoracic Oncology 2021, 16: s179. DOI: 10.1016/j.jtho.2021.01.260.
• Examination of factors associated with lymph node metastases in lung carcinoids: Results from a single institution retrospective cohort studyPathipati MP, Yohannan TK, Tian L, Hornbacker K, Benson JA, Berry GJ, Lui NS, Kunz PL, Padda SK. Examination of factors associated with lymph node metastases in lung carcinoids: Results from a single institution retrospective cohort study Lung Cancer 2021, 154: 186-194. PMID: 33551175, PMCID: PMC8026717, DOI: 10.1016/j.lungcan.2021.01.017.
• NANETS/SNMMI consensus statement on patient selection and appropriate use of 177 Lu-DOTATATE peptide receptor radionuclide therapyHope T, Bodei L, Chan J, El-Haddad G, Fidelman N, Kunz P, Mailman J, Menda Y, Metz D, Mittra E, Pryma D, Reidy-Lagunes D, Singh S, Strosberg J. NANETS/SNMMI consensus statement on patient selection and appropriate use of 177 Lu-DOTATATE peptide receptor radionuclide therapy Chinese Journal Of Nuclear Medicine And Molecular Imaging 2020, 40: 679-685. DOI: 10.3760/cma.j.cn321828-20200227-00071.
• Angiogenesis inhibitors in neuroendocrine tumours: finally coming of ageKunz PL. Angiogenesis inhibitors in neuroendocrine tumours: finally coming of age The Lancet Oncology 2020, 21: 1395-1397. PMID: 33152282, DOI: 10.1016/s1470-2045(20)30560-x.
• Cost-Effectiveness of Initial Versus Delayed Lanreotide for Treatment of Metastatic Enteropancreatic Neuroendocrine Tumors.Barnes JI, Lin JK, Gupta D, Owens DK, Goldhaber-Fiebert JD, Kunz PL. Cost-Effectiveness of Initial Versus Delayed Lanreotide for Treatment of Metastatic Enteropancreatic Neuroendocrine Tumors. Journal Of The National Comprehensive Cancer Network 2020, 18: 1200-1209. PMID: 32886901, DOI: 10.6004/jnccn.2020.7563.
• Commonwealth Neuroendocrine Tumour Research Collaboration and the North American Neuroendocrine Tumor Society Guidelines for the Diagnosis and Management of Patients With Lung Neuroendocrine Tumors: An International Collaborative Endorsement and Update of the 2015 European Neuroendocrine Tumor Society Expert Consensus GuidelinesSingh S, Bergsland EK, Card CM, Hope TA, Kunz PL, Laidley DT, Lawrence B, Leyden S, Metz DC, Michael M, Modahl LE, Myrehaug S, Padda SK, Pommier RF, Ramirez RA, Soulen M, Strosberg J, Sung A, Thawer A, Wei B, Xu B, Segelov E. Commonwealth Neuroendocrine Tumour Research Collaboration and the North American Neuroendocrine Tumor Society Guidelines for the Diagnosis and Management of Patients With Lung Neuroendocrine Tumors: An International Collaborative Endorsement and Update of the 2015 European Neuroendocrine Tumor Society Expert Consensus Guidelines Journal Of Thoracic Oncology 2020, 15: 1577-1598. PMID: 32663527, DOI: 10.1016/j.jtho.2020.06.021.
• PAM staining intensity of primary neuroendocrine neoplasms is a potential prognostic biomarkerHorton TM, Sundaram V, Lee CH, Hornbacker K, Van Vleck A, Benjamin KN, Zemek A, Longacre TA, Kunz PL, Annes JP. PAM staining intensity of primary neuroendocrine neoplasms is a potential prognostic biomarker Scientific Reports 2020, 10: 10943. PMID: 32616904, PMCID: PMC7331689, DOI: 10.1038/s41598-020-68071-6.
• North American Neuroendocrine Tumor Society Guide for Neuroendocrine Tumor Patient Health Care Providers During COVID-19Bergsland EK, Halperin DM, Dillon JS, Dasari NA, Kunz PL, Soares HP, Pryma D, Bodei L, Hope T, Soulen MC, Mailman J, Howe JR. North American Neuroendocrine Tumor Society Guide for Neuroendocrine Tumor Patient Health Care Providers During COVID-19 Pancreas 2020, 49: 10.1097/mpa.0000000000001561. PMID: 32433264, PMCID: PMC7253037, DOI: 10.1097/mpa.0000000000001561.
• A PHASE IIA STUDY REPOSITIONING DESIPRAMINE IN SMALL CELL LUNG CANCER AND OTHER HIGH-GRADE NEUROENDOCRINE TUMORSRiess JW, Jahchan NS, Das M, Koontz M, Kunz PL, Wakelee HA, Schatzberg A, Sage J, Neal JW. A PHASE IIA STUDY REPOSITIONING DESIPRAMINE IN SMALL CELL LUNG CANCER AND OTHER HIGH-GRADE NEUROENDOCRINE TUMORS Cancer Treatment And Research Communications 2020, 23: 100174. PMID: 32413603, PMCID: PMC7572629, DOI: 10.1016/j.ctarc.2020.100174.
• Patient Selection and Toxicities of PRRT for Metastatic Neuroendocrine Tumors and Research OpportunitiesShaheen S, Moradi F, Gamino G, Kunz PL. Patient Selection and Toxicities of PRRT for Metastatic Neuroendocrine Tumors and Research Opportunities Current Treatment Options In Oncology 2020, 21: 25. PMID: 32172368, DOI: 10.1007/s11864-020-0711-9.
• Time to Sustained Improvement in Bowel Movement Frequency with Telotristat Ethyl: Analyses of Phase III Studies in Carcinoid SyndromeDillon JS, Kulke MH, Hörsch D, Anthony LB, Warner RRP, Bergsland E, Welin S, O’Dorisio T, Kunz PL, McKee C, Lapuerta P, Banks P, Pavel M. Time to Sustained Improvement in Bowel Movement Frequency with Telotristat Ethyl: Analyses of Phase III Studies in Carcinoid Syndrome Journal Of Gastrointestinal Cancer 2020, 52: 212-221. PMID: 32146619, PMCID: PMC7714089, DOI: 10.1007/s12029-020-00375-2.
• Impact of liver tumour burden, alkaline phosphatase elevation, and target lesion size on treatment outcomes with 177Lu-Dotatate: an analysis of the NETTER-1 studyStrosberg J, Kunz PL, Hendifar A, Yao J, Bushnell D, Kulke MH, Baum RP, Caplin M, Ruszniewski P, Delpassand E, Hobday T, Verslype C, Benson A, Srirajaskanthan R, Pavel M, Mora J, Berlin J, Grande E, Reed N, Seregni E, Paganelli G, Severi S, Morse M, Metz DC, Ansquer C, Courbon F, Al-Nahhas A, Baudin E, Giammarile F, Taïeb D, Mittra E, Wolin E, O’Dorisio T, Lebtahi R, Deroose CM, Grana CM, Bodei L, Öberg K, Polack BD, He B, Mariani MF, Gericke G, Santoro P, Erion JL, Ravasi L, Krenning E. Impact of liver tumour burden, alkaline phosphatase elevation, and target lesion size on treatment outcomes with 177Lu-Dotatate: an analysis of the NETTER-1 study European Journal Of Nuclear Medicine And Molecular Imaging 2020, 47: 2372-2382. PMID: 32123969, PMCID: PMC7396396, DOI: 10.1007/s00259-020-04709-x.
• Analyse de la PFS de l’étude NETTER-1 chez des patients présentant une TNE intestinale dans des sous-groupes de mauvais pronostic avec atteinte hépatiqueRuszniewski P, Strosberg J, Kunz P, Hendifar A, Yao J, Bushnel D, Kulke M, Baum R, Caplin M, Delpassand E, Hobday T, Verslype C, Benson A, Polack B, Beilei H, Santaro P, Krenning E, group N. Analyse de la PFS de l’étude NETTER-1 chez des patients présentant une TNE intestinale dans des sous-groupes de mauvais pronostic avec atteinte hépatique Nuklearmedizin - NuclearMedicine 2020, 44: 96-97. DOI: 10.1016/j.mednuc.2020.01.108.
• NANETS/SNMMI Consensus Statement on Patient Selection and Appropriate Use of 177Lu-DOTATATE Peptide Receptor Radionuclide TherapyHope TA, Bodei L, Chan JA, El-Haddad G, Fidelman N, Kunz PL, Mailman J, Menda Y, Metz DC, Mittra ES, Pryma DA, Reidy-Lagunes DL, Singh S, Strosberg JR. NANETS/SNMMI Consensus Statement on Patient Selection and Appropriate Use of 177Lu-DOTATATE Peptide Receptor Radionuclide Therapy Journal Of Nuclear Medicine 2020, 61: 222-227. PMID: 32015164, PMCID: PMC9364765, DOI: 10.2967/jnumed.119.240911.
• Single institution experience with peptide receptor radionuclide therapy (PRRT) in neuroendocrine tumors (NET).Duan H, Ninatti G, Girod B, Ferri V, Kunz P, Fisher G, Moradi F, Davidzon G, Franc B, Iagaru A, Mari C. Single institution experience with peptide receptor radionuclide therapy (PRRT) in neuroendocrine tumors (NET). Journal Of Clinical Oncology 2020, 38: 623-623. DOI: 10.1200/jco.2020.38.4_suppl.623.
• Comprehensive genomic sequencing of high-grade neuroendocrine neoplasms.Sun T, Van Hummelen P, Martin B, Xia C, Lee H, Zhao L, Hornbacker K, Ji H, Kunz P. Comprehensive genomic sequencing of high-grade neuroendocrine neoplasms. Journal Of Clinical Oncology 2020, 38: 624-624. DOI: 10.1200/jco.2020.38.4_suppl.624.
• Surgery Versus Surveillance for Well‐Differentiated, Nonfunctional Pancreatic Neuroendocrine Tumors: An 11‐Year Analysis of the National Cancer DatabaseAssi HA, Mukherjee S, Kunz PL, Machiorlatti M, Vesely S, Pareek V, Hatoum H. Surgery Versus Surveillance for Well‐Differentiated, Nonfunctional Pancreatic Neuroendocrine Tumors: An 11‐Year Analysis of the National Cancer Database The Oncologist 2019, 25: e276-e283. PMID: 32043766, PMCID: PMC7011621, DOI: 10.1634/theoncologist.2019-0466.
• Comparison of definitive chemoradiation with 5-fluorouracil versus capecitabine in anal cancerPumpalova Y, Kozak MM, von Eyben R, Kunz P, Fisher G, Chang DT, Haraldsdottir S. Comparison of definitive chemoradiation with 5-fluorouracil versus capecitabine in anal cancer Journal Of Gastrointestinal Oncology 2019, 10: 605-615. PMID: 31392040, PMCID: PMC6657317, DOI: 10.21037/jgo.2019.02.17.
• Prognostic value of somatostatin receptor expressing tumor volume calculated from 68Ga-DOTATATE PET/CT in patients with well-differentiated neuroendocrine tumorsToriihara A, Baratto L, Nobashi T, Park S, Hatami N, Davidzon G, Kunz PL, Iagaru A. Prognostic value of somatostatin receptor expressing tumor volume calculated from 68Ga-DOTATATE PET/CT in patients with well-differentiated neuroendocrine tumors European Journal Of Nuclear Medicine And Molecular Imaging 2019, 46: 2244-2251. PMID: 31350603, DOI: 10.1007/s00259-019-04455-9.
• Evaluating the Role of Theranostics in Grade 3 Neuroendocrine NeoplasmsWaseem N, Aparici CM, Kunz PL. Evaluating the Role of Theranostics in Grade 3 Neuroendocrine Neoplasms Journal Of Nuclear Medicine 2019, 60: 882-891. PMID: 30850504, DOI: 10.2967/jnumed.118.217851.
• Temozolomide in grade III neuroendocrine neoplasms (G3 NENs): A multicenter retrospective review.Chan D, Bergsland E, Chan J, Gadgil R, Halfdanarson T, Hornbacker K, Kelly V, Kunz P, McGarrah P, Raj N, Reidy D, Thawer A, Whitman J, Wu L, Singh S. Temozolomide in grade III neuroendocrine neoplasms (G3 NENs): A multicenter retrospective review. Journal Of Clinical Oncology 2019, 37: 321-321. DOI: 10.1200/jco.2019.37.4_suppl.321.
• Organoid Modeling of the Tumor Immune MicroenvironmentNeal JT, Li X, Zhu J, Giangarra V, Grzeskowiak CL, Ju J, Liu IH, Chiou SH, Salahudeen AA, Smith AR, Deutsch BC, Liao L, Zemek AJ, Zhao F, Karlsson K, Schultz LM, Metzner TJ, Nadauld LD, Tseng YY, Alkhairy S, Oh C, Keskula P, Mendoza-Villanueva D, De La Vega FM, Kunz PL, Liao JC, Leppert JT, Sunwoo JB, Sabatti C, Boehm JS, Hahn WC, Zheng GXY, Davis MM, Kuo CJ. Organoid Modeling of the Tumor Immune Microenvironment Cell 2018, 175: 1972-1988.e16. PMID: 30550791, PMCID: PMC6656687, DOI: 10.1016/j.cell.2018.11.021.
• P1.12-06 Pulmonary Neuroendocrine (Carcinoid) Tumors: CommNETs/NANETS Endorsement and Update of the ENETs Best Practice ConsensusSingh S, Bergsland E, Card C, Hope T, Kunz P, Laidley D, Lawrence B, Leyden S, Michael M, Modahl L, Myrehaug S, Padda S, Pommier R, Ramirez R, Soulen M, Strosberg J, Thawer A, Wei B, Xu B, Segelov E. P1.12-06 Pulmonary Neuroendocrine (Carcinoid) Tumors: CommNETs/NANETS Endorsement and Update of the ENETs Best Practice Consensus Journal Of Thoracic Oncology 2018, 13: s575. DOI: 10.1016/j.jtho.2018.08.841.
• 1316P Impact of liver tumor burden on therapeutic effect of 177Lu-dotatate treatment in NETTER-1 studyStrosberg J, Hendifar A, Yao J, Kulke M, O’Dorisio T, Caplin M, Baum R, Kunz P, Hobday T, Wolin E, Mittra E, Oberg K, Ruszniewski P, Polack B, He B, Barton D, Santaro P, Krenning E. 1316P Impact of liver tumor burden on therapeutic effect of 177Lu-dotatate treatment in NETTER-1 study Annals Of Oncology 2018, 29: viii471. DOI: 10.1093/annonc/mdy293.009.
• 1322P The commonwealth neuroendocrine tumour collaboration (CommNETs) and North American neuroendocrine tumor society (NANETS) endorsement and update of European neuroendocrine tumor society (ENETS) best practice consensus for lung neuroendocrine tumors (LNET)Segelov E, Bergsland E, Card C, Hope T, Kunz P, Laidley D, Lawrence B, Leyden S, Michael M, Modahl L, Myrehaug S, Padda S, Pommier R, Ramirez R, Soulen M, Strosberg J, Thawer A, Wei B, Singh S. 1322P The commonwealth neuroendocrine tumour collaboration (CommNETs) and North American neuroendocrine tumor society (NANETS) endorsement and update of European neuroendocrine tumor society (ENETS) best practice consensus for lung neuroendocrine tumors (LNET) Annals Of Oncology 2018, 29: viii473. DOI: 10.1093/annonc/mdy293.015.
• The Power of TrustMou E, Schapira L, Kunz P. The Power of Trust JAMA Oncology 2018, 4: 1173-1174. PMID: 29710067, DOI: 10.1001/jamaoncol.2018.0495.
• Surgical and molecular characterization of primary and metastatic disease in a neuroendocrine tumor arising in a tailgut cystErdrich J, Schaberg KB, Khodadoust MS, Zhou L, Shelton AA, Visser BC, Ford JM, Alizadeh AA, Quake SR, Kunz PL, Beausang JF. Surgical and molecular characterization of primary and metastatic disease in a neuroendocrine tumor arising in a tailgut cyst Molecular Case Studies 2018, 4: a003004. PMID: 30087100, PMCID: PMC6169824, DOI: 10.1101/mcs.a003004.
• Long-Term Survivors of Pancreatic CancerKardosh A, Lichtensztajn DY, Gubens MA, Kunz PL, Fisher GA, Clarke CA. Long-Term Survivors of Pancreatic Cancer Pancreas 2018, 47: 958-966. PMID: 30074526, PMCID: PMC6095724, DOI: 10.1097/mpa.0000000000001133.
• NCCN Guidelines Insights: Neuroendocrine and Adrenal Tumors, Version 2.2018.Shah MH, Goldner WS, Halfdanarson TR, Bergsland E, Berlin JD, Halperin D, Chan J, Kulke MH, Benson AB, Blaszkowsky LS, Eads J, Engstrom PF, Fanta P, Giordano T, He J, Heslin MJ, Kalemkerian GP, Kandeel F, Khan SA, Kidwai WZ, Kunz PL, Kuvshinoff BW, Lieu C, Pillarisetty VG, Saltz L, Sosa JA, Strosberg JR, Sussman CA, Trikalinos NA, Uboha NA, Whisenant J, Wong T, Yao JC, Burns JL, Ogba N, Zuccarino-Catania G. NCCN Guidelines Insights: Neuroendocrine and Adrenal Tumors, Version 2.2018. Journal Of The National Comprehensive Cancer Network 2018, 16: 693-702. PMID: 29891520, DOI: 10.6004/jnccn.2018.0056.
• Health-Related Quality of Life in Patients With Progressive Midgut Neuroendocrine Tumors Treated With 177Lu-Dotatate in the Phase III NETTER-1 TrialStrosberg J, Wolin E, Chasen B, Kulke M, Bushnell D, Caplin M, Baum RP, Kunz P, Hobday T, Hendifar A, Oberg K, Sierra ML, Thevenet T, Margalet I, Ruszniewski P, Krenning E, Group O. Health-Related Quality of Life in Patients With Progressive Midgut Neuroendocrine Tumors Treated With 177Lu-Dotatate in the Phase III NETTER-1 Trial Journal Of Clinical Oncology 2018, 36: jco.2018.78.586. PMID: 29878866, PMCID: PMC6366953, DOI: 10.1200/jco.2018.78.5865.
• A randomized study of temozolomide or temozolomide and capecitabine in patients with advanced pancreatic neuroendocrine tumors: A trial of the ECOG-ACRIN Cancer Research Group (E2211).Kunz P, Catalano P, Nimeiri H, Fisher G, Longacre T, Suarez C, Yao J, Kulke M, Hendifar A, Shanks J, Shah M, Zalupski M, Schmulbach E, Reidy D, Strosberg J, O'Dwyer P, Benson A. A randomized study of temozolomide or temozolomide and capecitabine in patients with advanced pancreatic neuroendocrine tumors: A trial of the ECOG-ACRIN Cancer Research Group (E2211). Journal Of Clinical Oncology 2018, 36: 4004-4004. DOI: 10.1200/jco.2018.36.15_suppl.4004.
• A 20-year comparison of definitive chemoradiation with 5-FU versus capecitabine in anal cancer patients treated at a single institution.Pumpalova Y, Kozak M, von Eyben R, Kunz P, Fisher G, Chang D, Haraldsdottir S. A 20-year comparison of definitive chemoradiation with 5-FU versus capecitabine in anal cancer patients treated at a single institution. Journal Of Clinical Oncology 2018, 36: e15573-e15573. DOI: 10.1200/jco.2018.36.15_suppl.e15573.
• Changes in Weight Associated With Telotristat Ethyl in the Treatment of Carcinoid SyndromeWeickert MO, Kaltsas G, Hörsch D, Lapuerta P, Pavel M, Valle JW, Caplin ME, Bergsland E, Kunz PL, Anthony LB, Grande E, Öberg K, Welin S, Lombard-Bohas C, Ramage JK, Kittur A, Yang QM, Kulke MH. Changes in Weight Associated With Telotristat Ethyl in the Treatment of Carcinoid Syndrome Clinical Therapeutics 2018, 40: 952-962.e2. PMID: 29724499, DOI: 10.1016/j.clinthera.2018.04.006.
• Trust in neuroendocrine tumors: The importance of communication in rare and chronic malignancies.Mou E, Wittenberg T, Kunz P, Schapira L. Trust in neuroendocrine tumors: The importance of communication in rare and chronic malignancies. Journal Of Clinical Oncology 2018, 36: 75-75. DOI: 10.1200/jco.2018.36.7_suppl.75.
• A 20-year comparison of definitive chemoradiation with 5-FU versus capecitabine in anal cancer patients treated at Stanford.Pumpalova Y, Kozak M, von Eyben R, Fisher G, Kunz P, Chang D, Haraldsdottir S. A 20-year comparison of definitive chemoradiation with 5-FU versus capecitabine in anal cancer patients treated at Stanford. Journal Of Clinical Oncology 2018, 36: 710-710. DOI: 10.1200/jco.2018.36.4_suppl.710.
• Phase II study of epacadostat with pembrolizumab in metastatic or unresectable gastroesophageal junction and gastric adenocarcinoma requiring paired biopsies.Kardosh A, Tseng D, Sahaf B, Zomet A, Krupa J, Fisher G, Wang D, Mackall C, Kunz P. Phase II study of epacadostat with pembrolizumab in metastatic or unresectable gastroesophageal junction and gastric adenocarcinoma requiring paired biopsies. Journal Of Clinical Oncology 2018, 36: tps191-tps191. DOI: 10.1200/jco.2018.36.4_suppl.tps191.
• Telotristat ethyl in carcinoid syndrome: safety and efficacy in the TELECAST phase 3 trialPavel M, Gross DJ, Benavent M, Perros P, Srirajaskanthan R, Warner RRP, Kulke MH, Anthony LB, Kunz PL, Hörsch D, Weickert MO, Lapuerta P, Jiang W, Kassler-Taub K, Wason S, Fleming R, Fleming D, Garcia-Carbonero R. Telotristat ethyl in carcinoid syndrome: safety and efficacy in the TELECAST phase 3 trial Endocrine Related Cancer 2018, 25: 309-322. PMID: 29330194, PMCID: PMC5811631, DOI: 10.1530/erc-17-0455.
• Efficacy and safety of telotristat ethyl in patients with carcinoid syndrome inadequately controlled by somatostatin analogs: Analysis of the completed TELESTAR extension periodHorsch D, Kulke M, Caplin M, Anthony L, Bergsland E, Oberg K, Warner R, Kunz P, Pulido E, Valle J, Dillon J, Lapuerta P, Banks P, Jackson S, Pavel M. Efficacy and safety of telotristat ethyl in patients with carcinoid syndrome inadequately controlled by somatostatin analogs: Analysis of the completed TELESTAR extension period Endocrine Abstracts 2017 DOI: 10.1530/endoabs.52.p14.
• Weight change associated with telotristat ethyl in the treatment of carcinoid syndromeWeickert M, Kaltsas G, Horsch D, Lapuerta P, Pavel M, Valle J, Caplin M, Bergsland E, Kunz P, Anthony L, Grande E, Oberg K, Lombard-Bohas C, Fleming R, Kittur A, Arnold K, Kulke M, Welin S, Warner R, Yang Q. Weight change associated with telotristat ethyl in the treatment of carcinoid syndrome Endocrine Abstracts 2017 DOI: 10.1530/endoabs.52.p25.
• Carcinoid Syndrome Complicating a Pancreatic Neuroendocrine TumorGerson JN, Witteles RM, Chang DT, Beygui RE, Iagaru AH, Kunz PL. Carcinoid Syndrome Complicating a Pancreatic Neuroendocrine Tumor Pancreas 2017, 46: 1381-1385. PMID: 29040196, DOI: 10.1097/mpa.0000000000000932.
• Understanding the Patient Experience with Carcinoid Syndrome: Exit Interviews from a Randomized, Placebo-controlled Study of Telotristat EthylAnthony L, Ervin C, Lapuerta P, Kulke MH, Kunz P, Bergsland E, Hörsch D, Metz DC, Pasieka J, Pavlakis N, Pavel M, Caplin M, Öberg K, Ramage J, Evans E, Yang QM, Jackson S, Arnold K, Law L, DiBenedetti DB. Understanding the Patient Experience with Carcinoid Syndrome: Exit Interviews from a Randomized, Placebo-controlled Study of Telotristat Ethyl Clinical Therapeutics 2017, 39: 2158-2168. PMID: 29074312, DOI: 10.1016/j.clinthera.2017.09.013.
• Appropriate Use Criteria for Somatostatin Receptor PET Imaging in Neuroendocrine TumorsHope TA, Bergsland EK, Bozkurt MF, Graham M, Heaney AP, Herrmann K, Howe JR, Kulke MH, Kunz PL, Mailman J, May L, Metz DC, Millo C, O'Dorisio S, Reidy-Lagunes DL, Soulen MC, Strosberg JR. Appropriate Use Criteria for Somatostatin Receptor PET Imaging in Neuroendocrine Tumors Journal Of Nuclear Medicine 2017, 59: 66-74. PMID: 29025982, PMCID: PMC6910630, DOI: 10.2967/jnumed.117.202275.
• Understanding Neuroendocrine Tumors—A NET GainKunz PL. Understanding Neuroendocrine Tumors—A NET Gain JAMA Oncology 2017, 3: 1343-1344. PMID: 28448658, DOI: 10.1001/jamaoncol.2017.0575.
• 438PD Improved time to quality of life deterioration in patients with progressive midgut neuroendocrine tumors treated with 177Lu-DOTATATE: The NETTER-1 phase III trialStrosberg J, Wolin E, Chasen B, Kulke M, Bushnell D, Caplin M, Baum R, Kunz P, Hobday T, Hendifar A, Öberg K, Sierra M, Ruszniewski P, Krenning E. 438PD Improved time to quality of life deterioration in patients with progressive midgut neuroendocrine tumors treated with 177Lu-DOTATATE: The NETTER-1 phase III trial Annals Of Oncology 2017, 28: v146. DOI: 10.1093/annonc/mdx368.010.
• 440PD Efficacy and safety of telotristat ethyl in patients with carcinoid syndrome inadequately controlled by somatostatin analogs: Analysis of the completed TELESTAR extension periodHörsch D, Kulke M, Caplin M, Anthony L, Bergsland E, Öberg K, Warner R, Kunz P, Pulido E, Valle J, Dillon J, Lapuerta P, Banks P, Jackson S, Pavel M. 440PD Efficacy and safety of telotristat ethyl in patients with carcinoid syndrome inadequately controlled by somatostatin analogs: Analysis of the completed TELESTAR extension period Annals Of Oncology 2017, 28: v147. DOI: 10.1093/annonc/mdx368.012.
• The North American Neuroendocrine Tumor Society Consensus Guidelines for Surveillance and Medical Management of Midgut Neuroendocrine TumorsStrosberg JR, Halfdanarson TR, Bellizzi AM, Chan JA, Dillon JS, Heaney AP, Kunz PL, O’Dorisio T, Salem R, Segelov E, Howe JR, Pommier RF, Brendtro K, Bashir MA, Singh S, Soulen MC, Tang L, Zacks JS, Yao JC, Bergsland EK. The North American Neuroendocrine Tumor Society Consensus Guidelines for Surveillance and Medical Management of Midgut Neuroendocrine Tumors Pancreas 2017, 46: 707-714. PMID: 28609356, PMCID: PMC5642985, DOI: 10.1097/mpa.0000000000000850.
• Biologics in gastrointestinal and pancreatic neuroendocrine tumors.Liu IH, Kunz PL. Biologics in gastrointestinal and pancreatic neuroendocrine tumors. Journal Of Gastrointestinal Oncology 2017, 8: 457-465. PMID: 28736633, PMCID: PMC5506272, DOI: 10.21037/jgo.2016.12.09.
• Lanreotide depot (LAN) for symptomatic control of carcinoid syndrome (CS) in neuroendocrine tumor (NET) patients previously responsive to octreotide (OCT): Subanalysis of patient-reported symptoms from the phase III elect study.Fisher G, Pommier R, Wolin E, Kunz P, Liyanage N, Pitman Lowenthal S, Mirakhur B, Shaheen M, Vinik A. Lanreotide depot (LAN) for symptomatic control of carcinoid syndrome (CS) in neuroendocrine tumor (NET) patients previously responsive to octreotide (OCT): Subanalysis of patient-reported symptoms from the phase III elect study. Journal Of Clinical Oncology 2017, 35: 4088-4088. DOI: 10.1200/jco.2017.35.15_suppl.4088.
• Association of weight change with telotristat ethyl in the treatment of carcinoid syndrome.Weickert M, Kaltsas G, Hörsch D, Lapuerta P, Pavel M, Valle J, Caplin M, Bergsland E, Kunz P, Anthony L, Grande E, Oberg K, Warner R, Lombard-Bohas C, Welin S, Fleming R, Kittur A, Arnold K, Yang Q, Kulke M. Association of weight change with telotristat ethyl in the treatment of carcinoid syndrome. Journal Of Clinical Oncology 2017, 35: e15692-e15692. DOI: 10.1200/jco.2017.35.15_suppl.e15692.
• Abstract No. 38 Selection between locoregional embolotherapies for hepatic metastases from neuroendocrine tumor: Stratification by tumor burdenAbdelRazek M, Hwang W, Abdelmaksoud M, Louie J, Kothary N, Kunz P, Sze D. Abstract No. 38 Selection between locoregional embolotherapies for hepatic metastases from neuroendocrine tumor: Stratification by tumor burden Journal Of Vascular And Interventional Radiology 2017, 28: s19. DOI: 10.1016/j.jvir.2016.12.625.
• Quality-of-life findings in patients with midgut neuroendocrine tumors: Results of the NETTER-1 phase III trial.Strosberg J, Wolin E, Chasen B, Kulke M, Bushnell D, Caplin M, Baum R, Kunz P, Hobday T, Hendifar A, Oberg K, Lopera Sierra M, Kwekkeboom D, Ruszniewski P, Krenning E. Quality-of-life findings in patients with midgut neuroendocrine tumors: Results of the NETTER-1 phase III trial. Journal Of Clinical Oncology 2017, 35: 348-348. DOI: 10.1200/jco.2017.35.4_suppl.348.
• Efficacy of lanreotide depot (LAN) for symptomatic control of carcinoid syndrome (CS) in patients with neuroendocrine tumor (NET) previously responsive to octreotide (OCT): Subanalysis of patient-reported symptoms from the phase III ELECT study.Pommier R, Fisher G, Wolin E, Kunz P, Liyanage N, Pitman Lowenthal S, Mirakhur B, Shaheen M, Vinik A. Efficacy of lanreotide depot (LAN) for symptomatic control of carcinoid syndrome (CS) in patients with neuroendocrine tumor (NET) previously responsive to octreotide (OCT): Subanalysis of patient-reported symptoms from the phase III ELECT study. Journal Of Clinical Oncology 2017, 35: 378-378. DOI: 10.1200/jco.2017.35.4_suppl.378.
• Phase 3 Trial of 177Lu-Dotatate for Midgut Neuroendocrine TumorsStrosberg J, El-Haddad G, Wolin E, Hendifar A, Yao J, Chasen B, Mittra E, Kunz PL, Kulke MH, Jacene H, Bushnell D, O'Dorisio TM, Baum RP, Kulkarni HR, Caplin M, Lebtahi R, Hobday T, Delpassand E, Van Cutsem E, Benson A, Srirajaskanthan R, Pavel M, Mora J, Berlin J, Grande E, Reed N, Seregni E, Öberg K, Lopera Sierra M, Santoro P, Thevenet T, Erion JL, Ruszniewski P, Kwekkeboom D, Krenning E. Phase 3 Trial of 177Lu-Dotatate for Midgut Neuroendocrine Tumors New England Journal Of Medicine 2017, 376: 125-135. PMID: 28076709, PMCID: PMC5895095, DOI: 10.1056/nejmoa1607427.
• NETTER-1 Phase III in Patients with Midgut Neuroendocrine Tumors Treated with 177Lu-Dotatate: Efficacy, Safety, QoL Results and Subgroup AnalysisStrosberg J, Wolin E, Chasen B, Kulke M, Bushnell D, Caplin M, Baum R, Kunz P, Hobday T, Hendifar A, Oberg K, Lopera S, Kwekkeboom D, Ruszniewski P, Krenning E. NETTER-1 Phase III in Patients with Midgut Neuroendocrine Tumors Treated with 177Lu-Dotatate: Efficacy, Safety, QoL Results and Subgroup Analysis Endocrine Abstracts 2016 DOI: 10.1530/endoabs.47.oc8.
• Efficacy and safety of telotristat etiprate in patients with carcinoid syndrome not adequately controlled by somatostatin analog therapy: Analysis of the ongoing TELESTAR extension periodHorsch D, Kulke M, Caplin M, Anthony L, Bergsland E, Oberg K, Welin S, Warner R, Lombard-Bohas C, Kunz P, Valle J, Fleming D, Lapuerta P, Banks P, Pavel M. Efficacy and safety of telotristat etiprate in patients with carcinoid syndrome not adequately controlled by somatostatin analog therapy: Analysis of the ongoing TELESTAR extension period Endocrine Abstracts 2016 DOI: 10.1530/endoabs.46.oc3.
• Assessing treatment benefit of telotristat etiprate in patients with carcinoid syndrome: Patient exit interviewsAnthony L, Horsch D, Ervin C, Kulke M, Pavel M, Bergsland E, Caplin M, Oberg K, Warner R, Kunz P, Metz D, Pasieka J, Pavlakis N, DiBenedetti D, Haydysch E, Yang Q, Jackson S, Arnold K, Law L, Lapuerta P. Assessing treatment benefit of telotristat etiprate in patients with carcinoid syndrome: Patient exit interviews Endocrine Abstracts 2016 DOI: 10.1530/endoabs.46.p11.
• Oxaliplatin–Fluoropyrimidine Chemotherapy Plus Bevacizumab in Advanced Neuroendocrine TumorsKunz PL, Balise RR, Fehrenbacher L, Pan M, Venook AP, Fisher GA, Tempero MA, Ko AH, Korn WM, Hwang J, Bergsland EK. Oxaliplatin–Fluoropyrimidine Chemotherapy Plus Bevacizumab in Advanced Neuroendocrine Tumors Pancreas 2016, 45: 1394-1400. PMID: 27171514, DOI: 10.1097/mpa.0000000000000659.
• Telotristat Ethyl, a Tryptophan Hydroxylase Inhibitor for the Treatment of Carcinoid SyndromeKulke MH, Hörsch D, Caplin ME, Anthony LB, Bergsland E, Öberg K, Welin S, Warner RR, Lombard-Bohas C, Kunz PL, Grande E, Valle JW, Fleming D, Lapuerta P, Banks P, Jackson S, Zambrowicz B, Sands AT, Pavel M. Telotristat Ethyl, a Tryptophan Hydroxylase Inhibitor for the Treatment of Carcinoid Syndrome Journal Of Clinical Oncology 2016, 35: 14-23. PMID: 27918724, DOI: 10.1200/jco.2016.69.2780.
• Effectiveness of Radiation Therapy for Low- to Intermediate-Grade Neuroendocrine TumorsCarter J, Aggarwal S, Radish K, Allen J, Koong A, Chang D, Loo B, Diehn M, Kunz P, Gensheimer M. Effectiveness of Radiation Therapy for Low- to Intermediate-Grade Neuroendocrine Tumors International Journal Of Radiation Oncology • Biology • Physics 2016, 96: e202-e203. DOI: 10.1016/j.ijrobp.2016.06.1100.
• 420PD NETTER-1 phase III in patients with midgut neuroendocrine tumors treated with 177Lu-dotatate: Efficacy, safety, QoL results and subgroup analysisStrosberg J, Wolin E, Chasen B, Kulke M, Bushnell D, Caplin M, Baum R, Kunz P, Hobday T, Hendifar A, Oberg K, Sierra M, Kwekkeboom D, Ruszniewski P, Krenning E. 420PD NETTER-1 phase III in patients with midgut neuroendocrine tumors treated with 177Lu-dotatate: Efficacy, safety, QoL results and subgroup analysis Annals Of Oncology 2016, 27: vi137. DOI: 10.1093/annonc/mdw369.05.
• 422PD Integrated placebo-controlled safety analysis from clinical studies of telotristat ethyl for the treatment of carcinoid syndromeKulke M, Hörsch D, Caplin M, Anthony L, Bergsland E, Oberg K, Welin S, Warner R, Bohas C, Kunz P, Grande E, Valle J, Lapuerta P, Banks P, Jackson S, Jiang W, Biran T, Pavel M. 422PD Integrated placebo-controlled safety analysis from clinical studies of telotristat ethyl for the treatment of carcinoid syndrome Annals Of Oncology 2016, 27: vi138. DOI: 10.1093/annonc/mdw369.07.
• 423PD Phase I, open-label, dose-escalation study of SNX-5422 plus everolimus in neuroendocrine tumors (NETs)Gutierrez M, Giaccone G, Liu S, Rajan A, Guha U, Halfdanarson T, Curtis K, Kunz P, Gabrail N, Hinson J, Orlemans E. 423PD Phase I, open-label, dose-escalation study of SNX-5422 plus everolimus in neuroendocrine tumors (NETs) Annals Of Oncology 2016, 27: vi138. DOI: 10.1093/annonc/mdw369.08.
• 438P Efficacy of lanreotide autogel/depot (LAN) vs placebo (PBO) for symptomatic control of carcinoid syndrome (CS) in neuroendocrine tumor (NET) patients from the ELECT studyWolin E, Fisher G, Kunz P, Liyanage N, Lowenthal S, Mirakhur B, Pommier R, Shaheen M, Vinik A. 438P Efficacy of lanreotide autogel/depot (LAN) vs placebo (PBO) for symptomatic control of carcinoid syndrome (CS) in neuroendocrine tumor (NET) patients from the ELECT study Annals Of Oncology 2016, 27: vi143. DOI: 10.1093/annonc/mdw369.23.
• 440P Longer term efficacy of lanreotide autogel/depot (LAN) for symptomatic treatment of carcinoid syndrome (CS) in neuroendocrine tumor (NET) patients from the ELECT open label studyFisher G, Wolin E, Kunz P, Liyanage N, Mirakhur B, Lowenthal S, Pommier R, Shaheen M, Vinik A. 440P Longer term efficacy of lanreotide autogel/depot (LAN) for symptomatic treatment of carcinoid syndrome (CS) in neuroendocrine tumor (NET) patients from the ELECT open label study Annals Of Oncology 2016, 27: vi144. DOI: 10.1093/annonc/mdw369.25.
• Longer Term Efficacy of Lanreotide Autogel/Depot (LAN) for Symptomatic Treatment of Carcinoid Syndrome (CS) in Neuroendocrine Tumor (NET) Patients from the ELECT Open Label Study: 2016 ACG Presidential Poster AwardFisher G, Wolin E, Kunz P, Liyanage N, Mirakhur B, Lowenthal S, Pommier R, Shaheen M, Vinik A. Longer Term Efficacy of Lanreotide Autogel/Depot (LAN) for Symptomatic Treatment of Carcinoid Syndrome (CS) in Neuroendocrine Tumor (NET) Patients from the ELECT Open Label Study: 2016 ACG Presidential Poster Award The American Journal Of Gastroenterology 2016, 111: s457-s458. DOI: 10.14309/00000434-201610001-01052.
• Efficacy of Lanreotide Autogel/Depot (LAN) vs Placebo (PBO) for Symptomatic Control of Carcinoid Syndrome (CS) in Neuroendocrine Tumor (NET) Patients from the ELECT StudyWolin E, Fisher G, Kunz P, Liyanage N, Lowenthal S, Mirakhur B, Pommier R, Shaheen M, Vinik A. Efficacy of Lanreotide Autogel/Depot (LAN) vs Placebo (PBO) for Symptomatic Control of Carcinoid Syndrome (CS) in Neuroendocrine Tumor (NET) Patients from the ELECT Study The American Journal Of Gastroenterology 2016, 111: s468. DOI: 10.14309/00000434-201610001-01076.
• Efficacy and safety of telotristat etiprate in patients with carcinoid syndrome not adequately controlled by somatostatin analog therapy: Analysis of the ongoing TELESTAR extension periodHörsch D, Kulke M, Caplin M, Anthony L, Bergsland E, Öberg K, Welin S, Warner R, Lombard-Bohas C, Kunz P, Grande E, Valle J, Fleming D, Lapuerta P, Jackson S, Zambrowicz B, Sands A, Pavel M. Efficacy and safety of telotristat etiprate in patients with carcinoid syndrome not adequately controlled by somatostatin analog therapy: Analysis of the ongoing TELESTAR extension period Zeitschrift Für Gastroenterologie 2016, 54 DOI: 10.1055/s-0036-1587175.
• O-009 NETTER-1 phase III: efficacy and safety results in patients with midgut neuroendocrine tumors treated with 177Lu-dotatateStrosberg J, Wolin E, Chasen B, Kulke M, Bushnell D, Chaplin M, Baum R, Kunz P, Hobday T, Oberg K, Sierra M, Kwekkeboom D, Ruszniewski P, Krenning E, Hendifar A. O-009 NETTER-1 phase III: efficacy and safety results in patients with midgut neuroendocrine tumors treated with 177Lu-dotatate Annals Of Oncology 2016, 27: ii121. DOI: 10.1093/annonc/mdw198.09.
• Neuroendocrine tumors of the pancreas: Degree of cystic component predicts prognosisCloyd JM, Kopecky KE, Norton JA, Kunz PL, Fisher GA, Visser BC, Dua MM, Park WG, Poultsides GA. Neuroendocrine tumors of the pancreas: Degree of cystic component predicts prognosis Surgery 2016, 160: 708-713. PMID: 27216830, DOI: 10.1016/j.surg.2016.04.005.
• Metastatic melanoma, glioblastoma and high-grade extrapulmonary neuroendocrine carcinomas (NECs) as novel indications for rovalpituzumab tesirine: A delta-like protein 3 (DLL3)-targeted antibody-drug conjugate (ADC).Peng S, Saunders L, Bheddah S, Williams S, Aggarwal R, Shea J, Lee E, Huang J, Zemek A, Longacre T, Ball D, Scaife C, Nelkin B, Anthony L, Kunz P, Small E, Dylla S. Metastatic melanoma, glioblastoma and high-grade extrapulmonary neuroendocrine carcinomas (NECs) as novel indications for rovalpituzumab tesirine: A delta-like protein 3 (DLL3)-targeted antibody-drug conjugate (ADC). Journal Of Clinical Oncology 2016, 34: 11611-11611. DOI: 10.1200/jco.2016.34.15_suppl.11611.
• NETTER-1 phase III: Efficacy and safety results in patients with midgut neuroendocrine tumors treated with 177 Lu-DOTATATE.Strosberg J, Wolin E, Chasen B, Kulke M, Bushnell D, Caplin M, Baum R, Hobday T, Hendifar A, Oberg K, Lopera Sierra M, Kwekkeboom D, Ruszniewski P, Krenning E, Kunz P. NETTER-1 phase III: Efficacy and safety results in patients with midgut neuroendocrine tumors treated with 177 Lu-DOTATATE. Journal Of Clinical Oncology 2016, 34: 4005-4005. DOI: 10.1200/jco.2016.34.15_suppl.4005.
• A Multi-institutional Analysis of Duodenal Neuroendocrine Tumors: Tumor Biology Rather than Extent of Resection Dictates PrognosisMargonis GA, Samaha M, Kim Y, Postlewait LM, Kunz P, Maithel S, Tran T, Berger N, Gamblin TC, Mullen MG, Bauer TW, Pawlik TM. A Multi-institutional Analysis of Duodenal Neuroendocrine Tumors: Tumor Biology Rather than Extent of Resection Dictates Prognosis Journal Of Gastrointestinal Surgery 2016, 20: 1098-1105. PMID: 27008594, DOI: 10.1007/s11605-016-3135-x.
• Role of Somatostatin Analogues in the Treatment of Neuroendocrine TumorsNarayanan S, Kunz PL. Role of Somatostatin Analogues in the Treatment of Neuroendocrine Tumors Hematology/Oncology Clinics Of North America 2016, 30: 163-177. PMID: 26614375, DOI: 10.1016/j.hoc.2015.09.008.
• NETTER-1 phase III: Progression-free survival, radiographic response, and preliminary overall survival results in patients with midgut neuroendocrine tumors treated with 177-Lu-Dotatate.Strosberg J, Wolin E, Chasen B, Kulke M, Bushnell D, Caplin M, Baum R, Kunz P, Hobday T, Hendifar A, Oberg K, Lopera Sierra M, Kwekkeboom D, Ruszniewski P, Krenning E. NETTER-1 phase III: Progression-free survival, radiographic response, and preliminary overall survival results in patients with midgut neuroendocrine tumors treated with 177-Lu-Dotatate. Journal Of Clinical Oncology 2016, 34: 194-194. DOI: 10.1200/jco.2016.34.4_suppl.194.
• Abstract B26: RRx-001, a novel epigenetic modulator: Resensitization to previously failed therapy in the ongoing phase 2 colorectal cancer study, ROCKETReid T, Fisher G, Carter C, Cho-Phan C, Kunz P, Oronsky B, Fanger G, Stirn M, Caroen S, Parker C, Scicinski J. Abstract B26: RRx-001, a novel epigenetic modulator: Resensitization to previously failed therapy in the ongoing phase 2 colorectal cancer study, ROCKET Cancer Research 2016, 76: b26-b26. DOI: 10.1158/1538-7445.chromepi15-b26.
• DNA-repair defects in pancreatic neuroendocrine tumors and potential clinical applicationsLiu IH, Ford JM, Kunz PL. DNA-repair defects in pancreatic neuroendocrine tumors and potential clinical applications Cancer Treatment Reviews 2015, 44: 1-9. PMID: 26924193, DOI: 10.1016/j.ctrv.2015.11.006.
• Safety and Efficacy of Lanreotide Depot Versus Placebo in Neuroendocrine Tumor Patients With a History of Carcinoid Syndrome and Prior Octreotide TherapyFisher G, Wolin E, Kunz P, Liyanage N, Gomez-Panzani E, Lowenthal S, Pommier R, Shaheen M, Vinik A. Safety and Efficacy of Lanreotide Depot Versus Placebo in Neuroendocrine Tumor Patients With a History of Carcinoid Syndrome and Prior Octreotide Therapy The American Journal Of Gastroenterology 2015, 110: s1007. DOI: 10.14309/00000434-201510001-02424.
• 37LBA Telotristat etiprate is effective in treating patients with carcinoid syndrome that is inadequately controlled by somatostatin analog therapy (the phase 3 TELESTAR clinical trial)Kulke M, Horsch D, Caplin M, Anthony L, Bergsland E, Oberg K, Welin S, Warner R, Lombard-Bohas C, Kunz P, Grande E, Valle J, Fleming D, Lapuerta P, Banks P, Jackson S, Wheeler D, Zambrowicz B, Sands A, Pavel M. 37LBA Telotristat etiprate is effective in treating patients with carcinoid syndrome that is inadequately controlled by somatostatin analog therapy (the phase 3 TELESTAR clinical trial) European Journal Of Cancer 2015, 51: s728. DOI: 10.1016/s0959-8049(16)31951-7.
• The Development Of RRx-001, A Novel Nitric-Oxide-Mediated Epigenetically Active Anticancer Agent.Scicinski J, Fisher G, Carter C, Cho-Phan C, Kunz P, Ning S, Knox S, Oronsky B, Caroen S, Parker C, Fanger G, Reid T. The Development Of RRx-001, A Novel Nitric-Oxide-Mediated Epigenetically Active Anticancer Agent. Redox Biology 2015, 5: 422. PMID: 28162292, DOI: 10.1016/j.redox.2015.09.035.
• Abstract CT119: Early results from a phase II study of RRx-001, a novel, triple epigenetic inhibitor, showing resensitization to irinotecan in colorectal cancerReid T, Fisher G, Carter C, Cho-Phan C, Kunz P, Oronsky B, Fanger G, Caroen S, Parker C, Scicinski J. Abstract CT119: Early results from a phase II study of RRx-001, a novel, triple epigenetic inhibitor, showing resensitization to irinotecan in colorectal cancer 2015, ct119-ct119. DOI: 10.1158/1538-7445.am2015-ct119.
• Randomized phase II study of everolimus (E) versus everolimus plus bevacizumab (E+B) in patients (Pts) with locally advanced or metastatic pancreatic neuroendocrine tumors (pNET), CALGB 80701 (Alliance).Kulke M, Niedzwiecki D, Foster N, Fruth B, Kunz P, Kennecke H, Wolin E, Venook A. Randomized phase II study of everolimus (E) versus everolimus plus bevacizumab (E+B) in patients (Pts) with locally advanced or metastatic pancreatic neuroendocrine tumors (pNET), CALGB 80701 (Alliance). Journal Of Clinical Oncology 2015, 33: 4005-4005. DOI: 10.1200/jco.2015.33.15_suppl.4005.
• A randomized study of temozolomide or temozolomide and capecitabine in patients with advanced pancreatic neuroendocrine tumors: A trial of the ECOG-ACRIN Cancer Research Group (E2211).Kunz P, Catalano P, Nimeiri H, Fisher G, Longacre T, Schrijver I, Reidy D, Strosberg J, O'Dwyer P, Benson A. A randomized study of temozolomide or temozolomide and capecitabine in patients with advanced pancreatic neuroendocrine tumors: A trial of the ECOG-ACRIN Cancer Research Group (E2211). Journal Of Clinical Oncology 2015, 33: tps4145-tps4145. DOI: 10.1200/jco.2015.33.15_suppl.tps4145.
• Phase II pilot study of single-agent etirinotecan pegol (NKTR-102) in bevacizumab-resistant high grade gliomaNagpal S, Recht CK, Bertrand S, Thomas RP, Ajlan A, Pena J, Gershon M, Coffey G, Kunz PL, Li G, Recht LD. Phase II pilot study of single-agent etirinotecan pegol (NKTR-102) in bevacizumab-resistant high grade glioma Journal Of Neuro-Oncology 2015, 123: 277-282. PMID: 25935109, PMCID: PMC4452613, DOI: 10.1007/s11060-015-1795-0.
• New and Emerging Treatment Options for Gastroenteropancreatic Neuroendocrine Tumors.Phan AT, Kunz PL, Reidy-Lagunes DL. New and Emerging Treatment Options for Gastroenteropancreatic Neuroendocrine Tumors. Clinical Advances In Hematology And Oncology 2015, 13: 1-18; quiz 1 p following 18. PMID: 26430956.
• Carcinoid and Neuroendocrine Tumors: Building on SuccessKunz PL. Carcinoid and Neuroendocrine Tumors: Building on Success Journal Of Clinical Oncology 2015, 33: 1855-1863. PMID: 25918282, DOI: 10.1200/jco.2014.60.2532.
• Beyond biologics: is there a role for systemic cytotoxic chemotherapy in neuroendocrine tumors?Narayanan S, Kunz P. Beyond biologics: is there a role for systemic cytotoxic chemotherapy in neuroendocrine tumors? International Journal Of Endocrine Oncology 2015, 2: 13-20. DOI: 10.2217/ije.14.37.
• Pretreatment lab values to predict overall survival in patients with primary unresectable pancreatic adenocarcinoma treated with SBRT.Alagappan M, Pollom E, von Eyben R, Kunz P, Fisher G, Ford J, Poultsides G, Visser B, Norton J, Kamaya A, Columbo L, Koong A, Chang D. Pretreatment lab values to predict overall survival in patients with primary unresectable pancreatic adenocarcinoma treated with SBRT. Journal Of Clinical Oncology 2015, 33: 433-433. DOI: 10.1200/jco.2015.33.3_suppl.433.
• Role of somatostatin analogues in the treatment of neuroendocrine tumors.Narayanan S, Kunz PL. Role of somatostatin analogues in the treatment of neuroendocrine tumors. Journal Of The National Comprehensive Cancer Network 2015, 13: 109-17; quiz 117. PMID: 25583773, DOI: 10.6004/jnccn.2015.0012.
• Neuroendocrine tumors, version 1.2015.Kulke MH, Shah MH, Benson AB, Bergsland E, Berlin JD, Blaszkowsky LS, Emerson L, Engstrom PF, Fanta P, Giordano T, Goldner WS, Halfdanarson TR, Heslin MJ, Kandeel F, Kunz PL, Kuvshinoff BW, Lieu C, Moley JF, Munene G, Pillarisetty VG, Saltz L, Sosa JA, Strosberg JR, Vauthey JN, Wolfgang C, Yao JC, Burns J, Freedman-Cass D. Neuroendocrine tumors, version 1.2015. Journal Of The National Comprehensive Cancer Network : JNCCN 2015, 13: 78-108. PMID: 25583772, DOI: 10.6004/jnccn.2015.0011.
• Phase II clinical trial of pasireotide long-acting repeatable in patients with metastatic neuroendocrine tumorsCives M, Kunz P, Morse B, Coppola D, Schell M, Campos T, Nguyen P, Nandoskar P, Khandelwal V, Strosberg J. Phase II clinical trial of pasireotide long-acting repeatable in patients with metastatic neuroendocrine tumors Endocrine Related Cancer 2014, 22: 1-9. PMID: 25376618, PMCID: PMC4643672, DOI: 10.1530/erc-14-0360.
• Single- versus Multifraction Stereotactic Body Radiation Therapy for Pancreatic Adenocarcinoma: Outcomes and ToxicityPollom EL, Alagappan M, von Eyben R, Kunz PL, Fisher GA, Ford JA, Poultsides GA, Visser BC, Norton JA, Kamaya A, Cox VL, Columbo LA, Koong AC, Chang DT. Single- versus Multifraction Stereotactic Body Radiation Therapy for Pancreatic Adenocarcinoma: Outcomes and Toxicity International Journal Of Radiation Oncology • Biology • Physics 2014, 90: 918-925. PMID: 25585785, DOI: 10.1016/j.ijrobp.2014.06.066.
• Stereotactic Body Radiotherapy for Pancreatic Adenocarcinoma: Single versus Multi-FractionPollom E, Alagappan M, Cox V, Kamaya A, Kunz P, Poultsides G, Visser B, Koong A, Chang D. Stereotactic Body Radiotherapy for Pancreatic Adenocarcinoma: Single versus Multi-Fraction International Journal Of Radiation Oncology • Biology • Physics 2014, 90: s50. DOI: 10.1016/j.ijrobp.2014.05.184.
• Postradiotherapy CA19-9 Kinetics Correlate With Outcomes in Patients With Pancreatic AdenocarcinomaShultz DB, Chan C, Shaffer JL, Kunz PL, Koong AC, Chang DT. Postradiotherapy CA19-9 Kinetics Correlate With Outcomes in Patients With Pancreatic Adenocarcinoma Pancreas 2014, 43: 777-783. PMID: 24632549, DOI: 10.1097/mpa.0000000000000098.
• Etirinotecan pegol (EP, NKTR-102) in the treatment of high-grade glioma (HGG): A phase 2 trial.Nagpal S, Recht C, Imtiaz U, Bertrand S, Thomas R, Ajlan A, Pena J, Gershon M, Kunz P, Li G, Recht L. Etirinotecan pegol (EP, NKTR-102) in the treatment of high-grade glioma (HGG): A phase 2 trial. Journal Of Clinical Oncology 2014, 32: 2096-2096. DOI: 10.1200/jco.2014.32.15_suppl.2096.
• Randomized open-label phase 2 study of MM-111 and paclitaxel (PTX) with trastuzumab (TRAS) in patients with HER2-expressing carcinomas of the distal esophagus, gastroesophageal (GE) junction, and stomach who have failed front-line metastatic or locally advanced therapy.Denlinger C, Sym S, Bendell J, Alsina M, Watkins D, Chao Y, Cubillo A, Kunz P, Sun W, Baeksgaard L, Chen L, Horgan K, Frye S, Kudla A, McDonagh C, Czibere A, Moyo V, Chibaudel B, Bang Y. Randomized open-label phase 2 study of MM-111 and paclitaxel (PTX) with trastuzumab (TRAS) in patients with HER2-expressing carcinomas of the distal esophagus, gastroesophageal (GE) junction, and stomach who have failed front-line metastatic or locally advanced therapy. Journal Of Clinical Oncology 2014, 32: tps4148-tps4148. DOI: 10.1200/jco.2014.32.15_suppl.tps4148.
• Sa1141 Clinical and Immunohistochemical Features of High Grade Neuroendocrine Neoplasia of the Gastrointestinal TractDiMaio M, Zemek A, Kwok S, Kunz P, Longacre T. Sa1141 Clinical and Immunohistochemical Features of High Grade Neuroendocrine Neoplasia of the Gastrointestinal Tract Gastroenterology 2014, 146: s-210-s-211. DOI: 10.1016/s0016-5085(14)60745-9.
• A phase II study of capecitabine, carboplatin, and bevacizumab for metastatic or unresectable gastroesophageal junction and gastric adenocarcinoma.Kunz P, Nandoskar P, Koontz M, Ji H, Ford J, Balise R, Kamaya A, Rubin D, Fisher G. A phase II study of capecitabine, carboplatin, and bevacizumab for metastatic or unresectable gastroesophageal junction and gastric adenocarcinoma. Journal Of Clinical Oncology 2014, 32: 115-115. DOI: 10.1200/jco.2014.32.3_suppl.115.
• A novel biomarker panel examining response to adjuvant pancreatic cancer therapy in RTOG 9704.Heestand G, Murphy J, Moughan J, Regine W, Luo J, Graber M, Kunz P, Fisher G, Guha C, Lin B, Mowat R, Gaur R, Buyyounouski M, Chen Y, Chang D, Koong A. A novel biomarker panel examining response to adjuvant pancreatic cancer therapy in RTOG 9704. Journal Of Clinical Oncology 2014, 32: 176-176. DOI: 10.1200/jco.2014.32.3_suppl.176.
• Phase II clinical trial of pasireotide LAR in patients with metastatic neuroendocrine tumors.Strosberg J, Jump H, Valone T, Weber J, Khandelwal V, Kunz P. Phase II clinical trial of pasireotide LAR in patients with metastatic neuroendocrine tumors. Journal Of Clinical Oncology 2014, 32: 241-241. DOI: 10.1200/jco.2014.32.3_suppl.241.
• Outcomes and toxicity of SBRT for patients with unresectable pancreatic adenocarcinoma.Pollom E, Alagappan M, Chan C, Shultz D, Kunz P, Koong A, Chang D. Outcomes and toxicity of SBRT for patients with unresectable pancreatic adenocarcinoma. Journal Of Clinical Oncology 2014, 32: 317-317. DOI: 10.1200/jco.2014.32.3_suppl.317.
• False positive 18F-fluorodeoxyglucose positron emission tomography/computed tomography liver lesion mimicking metastasis in 2 patients with gastroesophageal cancerPaudel N, Kunz PL, Poultsides GA, Koong AC, Chang DT. False positive 18F-fluorodeoxyglucose positron emission tomography/computed tomography liver lesion mimicking metastasis in 2 patients with gastroesophageal cancer Practical Radiation Oncology 2013, 4: 368-371. PMID: 25407856, DOI: 10.1016/j.prro.2013.11.005.
• Reassessment of the Current American Joint Committee on Cancer Staging System for Pancreatic Neuroendocrine TumorsQadan M, Ma Y, Visser BC, Kunz PL, Fisher GA, Norton JA, Poultsides GA. Reassessment of the Current American Joint Committee on Cancer Staging System for Pancreatic Neuroendocrine Tumors Journal Of The American College Of Surgeons 2013, 218: 188-195. PMID: 24321190, DOI: 10.1016/j.jamcollsurg.2013.11.001.
• Pancreatic neuroendocrine tumours: hypoenhancement on arterial phase computed tomography predicts biological aggressivenessWorhunsky DJ, Krampitz GW, Poullos PD, Visser BC, Kunz PL, Fisher GA, Norton JA, Poultsides GA. Pancreatic neuroendocrine tumours: hypoenhancement on arterial phase computed tomography predicts biological aggressiveness Hepato Pancreato Biliary 2013, 16: 304-311. PMID: 23991643, PMCID: PMC3967881, DOI: 10.1111/hpb.12139.
• Diagnostic discrepancies between second-opinion and referring pathology reports of neuroendocrine tumors.Lin H, Longacre T, Khandelwal V, Balise R, Kunz P. Diagnostic discrepancies between second-opinion and referring pathology reports of neuroendocrine tumors. Journal Of Clinical Oncology 2013, 31: e15011-e15011. DOI: 10.1200/jco.2013.31.15_suppl.e15011.
• Consensus Guidelines for the Management and Treatment of Neuroendocrine TumorsKunz PL, Reidy-Lagunes D, Anthony LB, Bertino EM, Brendtro K, Chan JA, Chen H, Jensen RT, Kim MK, Klimstra DS, Kulke MH, Liu EH, Metz DC, Phan AT, Sippel RS, Strosberg JR, Yao JC. Consensus Guidelines for the Management and Treatment of Neuroendocrine Tumors Pancreas 2013, 42: 557-577. PMID: 23591432, PMCID: PMC4304762, DOI: 10.1097/mpa.0b013e31828e34a4.
• Phase II Study Evaluating 2 Dosing Schedules of Oral Foretinib (GSK1363089), cMET/VEGFR2 Inhibitor, in Patients with Metastatic Gastric CancerShah MA, Wainberg ZA, Catenacci DV, Hochster HS, Ford J, Kunz P, Lee FC, Kallender H, Cecchi F, Rabe DC, Keer H, Martin AM, Liu Y, Gagnon R, Bonate P, Liu L, Gilmer T, Bottaro DP. Phase II Study Evaluating 2 Dosing Schedules of Oral Foretinib (GSK1363089), cMET/VEGFR2 Inhibitor, in Patients with Metastatic Gastric Cancer PLOS ONE 2013, 8: e54014. PMID: 23516391, PMCID: PMC3597709, DOI: 10.1371/journal.pone.0054014.
• Diagnostic discrepancies between second-opinion and referring pathology reports of neuroendocrine tumors.Lin H, Longacre T, Khandelwal V, Balise R, Kunz P. Diagnostic discrepancies between second-opinion and referring pathology reports of neuroendocrine tumors. Journal Of Clinical Oncology 2013, 31: 154-154. DOI: 10.1200/jco.2013.31.4_suppl.154.
• Everolimus causing severe hypertriglyceridemia and acute pancreatitis.Subramaniam S, Zell JA, Kunz PL. Everolimus causing severe hypertriglyceridemia and acute pancreatitis. Journal Of The National Comprehensive Cancer Network : JNCCN 2013, 11: 5-9. PMID: 23307976, DOI: 10.6004/jnccn.2013.0003.
• Penile metastases originating from a pancreatic primary tumor: a case reportTello T, Zeidan Y, Bush K, Schwartz E, Kunz P, Chang D. Penile metastases originating from a pancreatic primary tumor: a case report Journal Of Radiation Oncology 2012, 2: 107-112. DOI: 10.1007/s13566-012-0076-1.
• Neoadjuvant imatinib for borderline resectable GIST.Koontz MZ, Visser BM, Kunz PL. Neoadjuvant imatinib for borderline resectable GIST. Journal Of The National Comprehensive Cancer Network 2012, 10: 1477-82; quiz 1482. PMID: 23221786, DOI: 10.6004/jnccn.2012.0154.
• Seventh Edition (2010) of the AJCC/UICC Staging System for Gastric Adenocarcinoma: Is there Room for Improvement?Patel MI, Rhoads KF, Ma Y, Ford JM, Visser BC, Kunz PL, Fisher GA, Chang DT, Koong A, Norton JA, Poultsides GA. Seventh Edition (2010) of the AJCC/UICC Staging System for Gastric Adenocarcinoma: Is there Room for Improvement? Annals Of Surgical Oncology 2012, 20: 1631-1638. PMID: 23149854, DOI: 10.1245/s10434-012-2724-5.
• Long-Term Survivors of Gastric Cancer: A California Population-Based StudyKunz PL, Gubens M, Fisher GA, Ford JM, Lichtensztajn DY, Clarke CA. Long-Term Survivors of Gastric Cancer: A California Population-Based Study Journal Of Clinical Oncology 2012, 30: 3507-3515. PMID: 22949151, DOI: 10.1200/jco.2011.35.8028.
• Capecitabine-Induced Chest Pain Relieved by DiltiazemAmbrosy AP, Kunz PL, Fisher GA, Witteles RM. Capecitabine-Induced Chest Pain Relieved by Diltiazem The American Journal Of Cardiology 2012, 110: 1623-1626. PMID: 22939579, DOI: 10.1016/j.amjcard.2012.07.026.
• Clinicopathologic and molecular features of sporadic early-onset colorectal adenocarcinoma: an adenocarcinoma with frequent signet ring cell differentiation, rectal and sigmoid involvement, and adverse morphologic features.Chang DT, Pai RK, Rybicki LA, Dimaio MA, Limaye M, Jayachandran P, Koong AC, Kunz PA, Fisher GA, Ford JM, Welton M, Shelton A, Ma L, Arber DA, Pai RK. Clinicopathologic and molecular features of sporadic early-onset colorectal adenocarcinoma: an adenocarcinoma with frequent signet ring cell differentiation, rectal and sigmoid involvement, and adverse morphologic features. Modern Pathology : An Official Journal Of The United States And Canadian Academy Of Pathology, Inc 2012, 25: 1128-39. PMID: 22481281, DOI: 10.1038/modpathol.2012.61.
• Neuroendocrine tumors.Kulke MH, Benson AB, Bergsland E, Berlin JD, Blaszkowsky LS, Choti MA, Clark OH, Doherty GM, Eason J, Emerson L, Engstrom PF, Goldner WS, Heslin MJ, Kandeel F, Kunz PL, Kuvshinoff BW, Moley JF, Pillarisetty VG, Saltz L, Schteingart DE, Shah MH, Shibata S, Strosberg JR, Vauthey JN, White R, Yao JC, Freedman-Cass DA, Dwyer MA. Neuroendocrine tumors. Journal Of The National Comprehensive Cancer Network : JNCCN 2012, 10: 724-64. PMID: 22679117, DOI: 10.6004/jnccn.2012.0075.
• A renaissance in therapeutic options for pancreatic neuroendocrine tumors.Kunz PL. A renaissance in therapeutic options for pancreatic neuroendocrine tumors. American Society Of Clinical Oncology Educational Book 2012, 271-4. PMID: 24451747, DOI: 10.14694/edbook_am.2012.32.136.
• A Renaissance in Therapeutic Options for Pancreatic Neuroendocrine TumorsKunz P. A Renaissance in Therapeutic Options for Pancreatic Neuroendocrine Tumors American Society Of Clinical Oncology Educational Book 2012, 271-274. DOI: 10.14694/edbook_am.2012.32.136.
• Pancreatic Neuroendocrine Tumors: Radiographic Calcifications Correlate with Grade and MetastasisPoultsides GA, Huang LC, Chen Y, Visser BC, Pai RK, Brooke Jeffrey R, Park WG, Chen AM, Kunz PL, Fisher GA, Norton JA. Pancreatic Neuroendocrine Tumors: Radiographic Calcifications Correlate with Grade and Metastasis Annals Of Surgical Oncology 2012, 19: 2295-2303. PMID: 22396008, DOI: 10.1245/s10434-012-2305-7.
• Phase I trial of ixabepilone administered as three oral doses each separated by 6 hours every 3 weeks in patients with advanced solid tumorsKunz PL, He AR, Colevas AD, Pishvaian MJ, Hwang JJ, Clemens PL, Messina M, Kaleta R, Abrahao F, Sikic BI, Marshall JL. Phase I trial of ixabepilone administered as three oral doses each separated by 6 hours every 3 weeks in patients with advanced solid tumors Investigational New Drugs 2012, 30: 2364-2370. PMID: 22331549, PMCID: PMC3703248, DOI: 10.1007/s10637-012-9800-3.
• HER2 Expression in Gastric and Gastroesophageal Junction Adenocarcinoma in a US PopulationKunz PL, Mojtahed A, Fisher GA, Ford JM, Chang DT, Balise RR, Bangs CD, Cherry AM, Pai RK. HER2 Expression in Gastric and Gastroesophageal Junction Adenocarcinoma in a US Population Applied Immunohistochemistry & Molecular Morphology 2012, 20: 13-24. PMID: 21617522, PMCID: PMC6402787, DOI: 10.1097/pai.0b013e31821c821c.
• Intensity-Modulated Radiotherapy for Pancreatic AdenocarcinomaAbelson JA, Murphy JD, Minn AY, Chung M, Fisher GA, Ford JM, Kunz P, Norton JA, Visser BC, Poultsides GA, Koong AC, Chang DT. Intensity-Modulated Radiotherapy for Pancreatic Adenocarcinoma International Journal Of Radiation Oncology • Biology • Physics 2011, 82: e595-e601. PMID: 22197234, DOI: 10.1016/j.ijrobp.2011.09.035.
• A rare case of an aldosterone secreting metastatic adrenocortical carcinoma and papillary thyroid carcinoma in a 31-year-old maleWanta SM, Basina M, Chang SD, Chang DT, Ford JM, Greco R, Kingham K, Merritt RE, Kunz PL. A rare case of an aldosterone secreting metastatic adrenocortical carcinoma and papillary thyroid carcinoma in a 31-year-old male Rare Tumors 2011, 3: e45. PMID: 22355500, PMCID: PMC3282450, DOI: 10.4081/rt.2011.e45.
• Multimodality Therapy for Esophageal Cancer: The Benefit of ChemoradiationVossler S, Bavan B, Kunz P, Ford J, Fisher G, Whyte R, Koong A, Chang D. Multimodality Therapy for Esophageal Cancer: The Benefit of Chemoradiation International Journal Of Radiation Oncology • Biology • Physics 2011, 81: s309. DOI: 10.1016/j.ijrobp.2011.06.497.
• Intensity-modulated radiation therapy versus conventional radiation therapy for squamous cell carcinoma of the anal canal.Bazan JG, Hara W, Hsu A, Kunz PA, Ford J, Fisher GA, Welton ML, Shelton A, Kapp DS, Koong AC, Goodman KA, Chang DT. Intensity-modulated radiation therapy versus conventional radiation therapy for squamous cell carcinoma of the anal canal. Cancer 2011, 117: 3342-51. PMID: 21287530, DOI: 10.1002/cncr.25901.
• Pancreatic endocrine tumors with major vascular abutment, involvement, or encasement and indication for resection.Norton JA, Harris EJ, Chen Y, Visser BC, Poultsides GA, Kunz PC, Fisher GA, Jensen RT. Pancreatic endocrine tumors with major vascular abutment, involvement, or encasement and indication for resection. Archives Of Surgery (Chicago, Ill. : 1960) 2011, 146: 724-32. PMID: 21690450, PMCID: PMC3122162, DOI: 10.1001/archsurg.2011.129.
• Bevacizumab (Bev) plus chemotherapy for advanced gastroesophageal adenocarcinoma (GC): Combined U.S. experience.Smyth E, Enzinger P, Li J, Vincitore M, Lacy J, El-Rayes B, Kunz P, Ford J, Robinson E, Kelsen D, Shah M. Bevacizumab (Bev) plus chemotherapy for advanced gastroesophageal adenocarcinoma (GC): Combined U.S. experience. Journal Of Clinical Oncology 2011, 29: 4056-4056. DOI: 10.1200/jco.2011.29.15_suppl.4056.
• Single-Fraction Stereotactic Body Radiation Therapy and Sequential Gemcitabine for the Treatment of Locally Advanced Pancreatic CancerSchellenberg D, Kim J, Christman-Skieller C, Chun CL, Columbo LA, Ford JM, Fisher GA, Kunz PL, Van Dam J, Quon A, Desser TS, Norton J, Hsu A, Maxim PG, Xing L, Goodman KA, Chang DT, Koong AC. Single-Fraction Stereotactic Body Radiation Therapy and Sequential Gemcitabine for the Treatment of Locally Advanced Pancreatic Cancer International Journal Of Radiation Oncology • Biology • Physics 2011, 81: 181-188. PMID: 21549517, DOI: 10.1016/j.ijrobp.2010.05.006.
• 18F-5-fluorouracil dynamic positron emission tomography/computed tomography shows decreased tracer activity after bevacizumab in colorectal metastasesZissen MH, Kunz P, Subbarayan M, Chin FT, Conti PS, Fisher GA, Quon A. 18F-5-fluorouracil dynamic positron emission tomography/computed tomography shows decreased tracer activity after bevacizumab in colorectal metastases Nuclear Medicine Communications 2011, 32: 343-347. PMID: 21412178, DOI: 10.1097/mnm.0b013e328344894b.
• Long-term survivorship in gastric cancer.Kunz P, Gubens M, Fisher G, Ford J, Lichtensztajn D, Clarke C. Long-term survivorship in gastric cancer. Journal Of Clinical Oncology 2011, 29: 14-14. DOI: 10.1200/jco.2011.29.4_suppl.14.
• Long-term survivorship in pancreatic adenocarcinoma.Gubens M, Kunz P, Fisher G, Ford J, Lichtensztajn D, Clarke C. Long-term survivorship in pancreatic adenocarcinoma. Journal Of Clinical Oncology 2011, 29: 175-175. DOI: 10.1200/jco.2011.29.4_suppl.175.
• The Evolution of Modern Systemic Agents for Colorectal CancerHeestand G, Kunz P, Fisher G. The Evolution of Modern Systemic Agents for Colorectal Cancer Radiation Medicine Rounds 2010, 1: 249-260. DOI: 10.5003/2151-4208.1.2.249.
• Expression of p16INK4A but not hypoxia markers or poly adenosine diphosphate‐ribose polymerase is associated with improved survival in patients with pancreatic adenocarcinomaChang DT, Chapman CH, Norton JA, Visser B, Fisher GA, Kunz P, Ford JM, Koong AC, Pai RK. Expression of p16INK4A but not hypoxia markers or poly adenosine diphosphate‐ribose polymerase is associated with improved survival in patients with pancreatic adenocarcinoma Cancer 2010, 116: 5179-5187. PMID: 20665497, DOI: 10.1002/cncr.25481.
• Advances in the treatment of gastroenteropancreatic neuroendocrine tumorsKunz PL, Fisher GA. Advances in the treatment of gastroenteropancreatic neuroendocrine tumors Clinical And Experimental Gastroenterology 2010, Volume 3: 79-86. PMID: 21694850, PMCID: PMC3108662, DOI: 10.2147/ceg.s5928.
• A phase II study of capecitabine, oxaliplatin, and bevacizumab for metastatic or unresectable neuroendocrine tumors.Kunz P, Kuo T, Zahn J, Kaiser H, Norton J, Visser B, Longacre T, Ford J, Balise R, Fisher G. A phase II study of capecitabine, oxaliplatin, and bevacizumab for metastatic or unresectable neuroendocrine tumors. Journal Of Clinical Oncology 2010, 28: 4104-4104. DOI: 10.1200/jco.2010.28.15_suppl.4104.
• A phase I study of an oral formulation of ixabepilone (ixa) in patients with advanced cancer.He A, Kunz P, Pishvaian M, Colevas A, Hwang J, Clemens P, Messina M, Kaleta R, Abrahao F, Sikic B. A phase I study of an oral formulation of ixabepilone (ixa) in patients with advanced cancer. Journal Of Clinical Oncology 2010, 28: e13090-e13090. DOI: 10.1200/jco.2010.28.15_suppl.e13090.
• Treatment of pancreatic cancer in patients age 70 or older.Christman-Skieller C, Heestand G, Fisher G, Kunz P, Ford J, Columbo L, Chang D, Koong A. Treatment of pancreatic cancer in patients age 70 or older. Journal Of Clinical Oncology 2010, 28: e14590-e14590. DOI: 10.1200/jco.2010.28.15_suppl.e14590.
• Comparison of intensity‐modulated radiotherapy and 3‐dimensional conformal radiotherapy as adjuvant therapy for gastric cancerMinn AY, Hsu A, La T, Kunz P, Fisher GA, Ford JM, Norton JA, Visser B, Goodman KA, Koong AC, Chang DT. Comparison of intensity‐modulated radiotherapy and 3‐dimensional conformal radiotherapy as adjuvant therapy for gastric cancer Cancer 2010, 116: 3943-3952. PMID: 20564136, DOI: 10.1002/cncr.25246.
• 18Fluorodeoxyglucose PET Is Prognostic of Progression-Free and Overall Survival in Locally Advanced Pancreas Cancer Treated With Stereotactic RadiotherapySchellenberg D, Quon A, Minn AY, Graves EE, Kunz P, Ford JM, Fisher GA, Goodman KA, Koong AC, Chang DT. 18Fluorodeoxyglucose PET Is Prognostic of Progression-Free and Overall Survival in Locally Advanced Pancreas Cancer Treated With Stereotactic Radiotherapy International Journal Of Radiation Oncology • Biology • Physics 2010, 77: 1420-1425. PMID: 20056345, DOI: 10.1016/j.ijrobp.2009.06.049.
• 37 Cancer of the StomachMinsky B, Ford J, Kunz P, Norton J. 37 Cancer of the Stomach 2010, 788-800. DOI: 10.1016/b978-1-4160-5897-7.00038-x.
• Identification of a biomarker panel using a multiplex proximity ligation assay improves accuracy of pancreatic cancer diagnosisChang ST, Zahn JM, Horecka J, Kunz PL, Ford JM, Fisher GA, Le QT, Chang DT, Ji H, Koong AC. Identification of a biomarker panel using a multiplex proximity ligation assay improves accuracy of pancreatic cancer diagnosis Journal Of Translational Medicine 2009, 7: 105. PMID: 20003342, PMCID: PMC2796647, DOI: 10.1186/1479-5876-7-105.
• Comparison of IMRT and 3D Conformal Radiotherapy for Adjuvant Therapy for Gastric CancerMinn A, Fisher G, Ford J, Kunz P, Norton J, Koong A, Chang D. Comparison of IMRT and 3D Conformal Radiotherapy for Adjuvant Therapy for Gastric Cancer International Journal Of Radiation Oncology • Biology • Physics 2009, 75: s259. DOI: 10.1016/j.ijrobp.2009.07.597.
• Assessment of two dosing schedules of GSK1363089 (GSK089), a dual MET/VEGFR2 inhibitor, in metastatic gastric cancer (GC): Interim results of a multicenter phase II studyJhawer M, Kindler H, Wainberg Z, Ford J, Kunz P, Tang L, McCallum S, Kallender H, Shah M. Assessment of two dosing schedules of GSK1363089 (GSK089), a dual MET/VEGFR2 inhibitor, in metastatic gastric cancer (GC): Interim results of a multicenter phase II study Journal Of Clinical Oncology 2009, 27: 4502-4502. DOI: 10.1200/jco.2009.27.15_suppl.4502.
• Adjuvant chemoradiotherapy with carboplatin and a fluoropyrimidine for resectable gastric and gastroesophageal junction cancer: A retrospective review of the Stanford experiencede Bruin M, Kunz P, Sharma V, Norton J, Bastidas J, Chang D, Koong A, Koong A, Balise R, Ford J, Fisher G. Adjuvant chemoradiotherapy with carboplatin and a fluoropyrimidine for resectable gastric and gastroesophageal junction cancer: A retrospective review of the Stanford experience Journal Of Clinical Oncology 2009, 27: e15674-e15674. DOI: 10.1200/jco.2009.27.15_suppl.e15674.
• Carboplatin and fluoropyrimidine-based treatment for metastatic gastric and gastroesophageal junction cancer: A retrospective review of the Stanford experienceKunz P, de Bruin M, Balise R, Fisher G, Ford J. Carboplatin and fluoropyrimidine-based treatment for metastatic gastric and gastroesophageal junction cancer: A retrospective review of the Stanford experience Journal Of Clinical Oncology 2009, 27: e15686-e15686. DOI: 10.1200/jco.2009.27.15_suppl.e15686.
• Phase II Trial of Single Fraction Stereotactic Body Radiotherapy Delivered by Trilogy Linear Accelerator for the Treatment of Locally Advanced Adenocarcinoma of the PancreasSchellenberg D, Kim J, Columbo L, Lee C, Fisher G, Kunz P, Maxim P, Goodman K, Chang D, Koong A. Phase II Trial of Single Fraction Stereotactic Body Radiotherapy Delivered by Trilogy Linear Accelerator for the Treatment of Locally Advanced Adenocarcinoma of the Pancreas International Journal Of Radiation Oncology • Biology • Physics 2008, 72: s127. DOI: 10.1016/j.ijrobp.2008.06.428.
• A phase II study of capecitabine, oxaliplatin, and bevacizumab for metastatic or unresectable neuroendocrine tumors: Preliminary resultsKunz P, Kuo T, Kaiser H, Norton J, Longacre T, Ford J, Fisher G. A phase II study of capecitabine, oxaliplatin, and bevacizumab for metastatic or unresectable neuroendocrine tumors: Preliminary results Journal Of Clinical Oncology 2008, 26: 15502-15502. DOI: 10.1200/jco.2008.26.15_suppl.15502.
• An update of a phase I/II study of the VEGF receptor tyrosine kinase inhibitor vatalanib and gemcitabine in patients with advanced pancreatic cancerKuo T, Cabebe E, Koong A, Norton J, Kunz P, Ford J, Kaiser H, Rogers J, Sikic B, Fisher G. An update of a phase I/II study of the VEGF receptor tyrosine kinase inhibitor vatalanib and gemcitabine in patients with advanced pancreatic cancer Journal Of Clinical Oncology 2008, 26: 15571-15571. DOI: 10.1200/jco.2008.26.15_suppl.15571.
• Phase I trial of preoperative cetuximab in combination with oxaliplatin, capecitabine, and radiation therapy for locally advanced rectal cancerCabebe E, Kuo T, Koong A, Welton M, Shelton A, Kunz P, Ford J, Sikic B, Kaiser H, Rogers J, Fisher G. Phase I trial of preoperative cetuximab in combination with oxaliplatin, capecitabine, and radiation therapy for locally advanced rectal cancer Journal Of Clinical Oncology 2008, 26: 15019-15019. DOI: 10.1200/jco.2008.26.15_suppl.15019.
• Escherichia coli O157:H7 infection in nursing homes: review of literature and report of recent outbreak.Reiss G, Kunz P, Koin D, Keeffe EB. Escherichia coli O157:H7 infection in nursing homes: review of literature and report of recent outbreak. Journal Of The American Geriatrics Society 2006, 54: 680-4. PMID: 16686882, DOI: 10.1111/j.1532-5415.2006.00682.x.
• Cost-effectiveness of photodynamic therapy for high-grade dysplasia in Barrett's esophagusVij R, Triadafilopoulos G, Owens DK, Kunz P, Sanders GD. Cost-effectiveness of photodynamic therapy for high-grade dysplasia in Barrett's esophagus Gastrointestinal Endoscopy 2004, 60: 739-756. PMID: 15557950, DOI: 10.1016/s0016-5107(04)02167-4.
• Tandem mass spectrometry and newborn screening: pilot data and review.Filiano JJ, Bellimer SG, Kunz PL. Tandem mass spectrometry and newborn screening: pilot data and review. Pediatric Neurology 2002, 26: 201-4. PMID: 11955927, DOI: 10.1016/s0887-8994(01)00384-8.